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ABSTRACT
Genomic instability is a hallmark of disorders in which DNA replication and repair genes
are dysfunctional. The tumor suppressor RECQ helicase gene BLM encodes the 3’-5’ DNA
Bloom syndrome helicase BLM, which plays important roles during DNA replication,
recombination and repair to maintain genome stability. Mutations within BLM cause Bloom
syndrome, an autosomal recessive disorder characterized by growth defects, immunodeficiency,
>10-fold higher sister chromatid exchange compared to normal cells, and an increased
predisposition to a wide range of cancers from an early age. Single nucleotide polymorphisms or
SNPs in BLM have been reported to be associated with susceptibility to a variety of
malignancies. However, these are non-coding SNPs with no evidence linking them to SNPs in
BLM exons. An overwhelming majority of nonsynonymous SNPs in BLM for which allelic
frequencies are known are rare. Together with their rarity in the human genome and a higher
likelihood of being functional, rare SNPs can be an important genetic basis of common human
diseases. And since almost all nonsynonymous SNPs in BLM are rare, they are prime candidates
for functional characterization to determine risk-association. A comprehensive functional
evaluation of coding BLM variants using a humanized yeast model identified six variants which
totally impair BLM function, with DNA damage sensitivity conferred by these alleles
comparable to Bloom syndrome-causing alleles in the human population. An intermediate
sensitivity to DNA damage was conferred by three other alleles. Here, functionally evaluated the
ability of 8 of these BLM variants to complement cellular defects in the Bloom syndrome
patient-derived GM08505 cell line including the elevated sister-chromatid exchanges frequency,
xi

delayed response to DNA damage, and hypersenstivity to DNA damaging agents. We
determined that five of these variants are incapable of complementing defects of the GM08505
cell line, which are candidates for adding to the list of thirteen currently known Bloom syndrome
causing missense mutations. We identified three other BLM variants that were incapable of
complementing the elevated sister-chromatid exchange frequency and delayed DNA-damage
response, but were able to suppress hypersensitivity to DNA damaging agents as well as
wildtype BLM. These intermediate BLM variants are hypomorphic which, instead of causing
Bloom syndrome, may confer increased cancer predisposition or lead to other Bloom‐syndrome‐
associated disorders like type‐2 diabetes.
The GM08505 cells used in the functional characterization of BLM variants is aneuploid.
Defects in DNA replication, telomere maintenance, chromosomal segregation, cell cycle
checkpoint activation, and DNA damage response cause chromosomal instability. Aneuploidy is
considered to be an outcome of chromosomal instability. Paradoxically, another school of
thought considers aneuploidy as the driver of chromosomal instability. It has been suggested that
variable expression of genes on aneuploid chromosomes can potentially dysfunction of their
protein product, leading to chromosomal instability phenotypes. It has been proposed that
chromosomal instability and aneuploidy are part of a vicious cycle which results is an
increasingly diverse karyotype directly impacting gene expression. Using genome engineering,
we generated and functionally characterized a diploid BLM knockout cell line. This cell line
exhibits cellular defects similar to the Bloom syndrome patient derived GM08505 cell line.
Being diploid and unaffected by uneven gene dosage, this cell line can provide a good system to
investigate dysregulated factors in the absence of BLM.
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The prevention of genomic instability depends on multiple pathways ensuring timely
progression of replication and appropriate response to DNA damage. BLM functions at the
crossroads of response pathways induced by DNA damage during replication. The canonical role
of BLM is dissolving double Holliday junction during homologous recombination- mediated
DNA double strand repair as part of the BLM/Topoisomerase IIIα /RMI1/RMI2 or BTR complex
to yield non-crossover products. Additionally, BLM functions in the key early step of resecting
double strand breaks to initiate DNA repair. BLM can also reverse the invasion of the resultant
single stranded 3’ overhangs in an anti-reombinogenic role and regulate recombinational DNA
repair. BLM functions to restart stalled replication forks resulting from DNA damage. Thus far,
most studies evaluating the role of BLM in replication have proposed models based on its role in
recovery from induced replication stress. However, delayed replication timing, increased
replication fork pausing, endogenous DNA damage, and activation of replication checkpoints in
unperturbed Bloom-syndrome cells point to a role for BLM in protecting the replisome
movement through the genome. A critical aspect of BLM functionality is its substrate specificity
to a variety of DNA structures. Notably, it can bind and unwind G-quadruplex structures in vitro
and has been associated with a functional role in unwinding such regions in vivo to aid replisome
movement with limited evidence. We immunoprecipitated BLM in mid-S-phase and performed a
mass spectrometric screen to identify novel interactors in a bid to identify mechanisms by which
BLM maintains genome stability during unperturbed replication. We show that Mcm6, an MCM
replicative helicase subunit, is a novel BLM interactor. BLM interacts with Mcm6 via multiple,
distinct binding sites in G1 phase, at active replisomes in S-phase, and during response to
replication stress induced DNA damage. We show that BLM is a constitutive component of
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active replisomes in during unperturbed replication. Finally, we uncover a potential novel role
for BLM in G1 requiring interaction with Mcm6.
Our data provides functional and mechanistic insight into polymorphisms in BLM,
and their implications for the general population. We have also engineered a diploid BLM
knockout cell line which can serve as a platform for investigating BLM variants in the absence of
uneven gene dosage as well as proteomic analysis to identify factors dysregulated in the absence
of BLM. We show that BLM is a component of active replisomes in an unperturbed S phase and
has a potentially novel function in G1.

xiv

CHAPTER ONE:
INTRODUCTION
Genomic stability is dependent on the tight regulation of and coordination between
cellular mechanisms involved in DNA metabolism. Factors responsible for faithful DNA
replication, DNA damage response, and timely checkpoint activation in the S-phase are key
mediators of cell cycle progression in the face of genotoxic stress. Genome instability results
when these factors are dysfunctional, manifesting as abnormal development, growth defects,
premature aging, and predisposition to cancers and tumorigenesis. At the cellular level, these are
characterized by hyperrecombination events, genome rearrangements, and aberrant chromosomal
structures [5-7]. Helicases are members of a group of enzymes involved in all aspects of nucleic
acid metabolism, including replication, expression, repair and recombination [8, 9]. They
function in these pathways by mediating the necessary step of ATP-dependent translocation
along DNA, RNA or DNA/RNA structures to unwind them with either a 5’→3’ or a 3’→5’
polarity. Identification of conserved helicase motifs based on structure and function analysis
have led them to be classified into six helicase superfamilies [10, 11]. Helicase superfamily 1
(SF1) and superfamily 2 (SF2) are the two largest of these and are structurally similar. SF1 and
SF2 members contain a conserved catalytic region known as the core helicase domain consisting
of two domains resembling the recombination protein RecA fold. The conserved helicase motifs
are localized to a cleft formed between the two RecA-like domains contains, forming the site of
binding and translocation along single strand DNA (ssDNA) [11, 14]. Furthermore, a β-hairpin
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has been found to localize outside this cleft in various SF1 and SF2 members and functions in
strand separation [14, 17]. Phylogenetic analysis of alignments to score sequence-specific
features and domain organization of SF1 and SF2 proteins has led to the sub-classification of
SF1 into three families and SF2 into nine families [14]. The RecQ helicase family belongs to
SF2 and plays important roles in maintaining genome stability [20-23].
THE RECQ HELICASE FAMILY
The family derives its name from the founding member RecQ, a helicase with 3’→5’
DNA unwinding activity and a component of the RecF pathway in Escherichia coli (E. coli)
[24]. Since then, other RecQ family members have been identified across various kingdoms of
life. While single cell organisms have one or two RecQ genes, higher eukaryotes have multiple
genes expressing proteins belonging to the RecQ family [25-27]. Five RecQ helicases have been
identified in humans - RECQL1, RECQL4, RECQL5, WRN, and BLM. Structurally, RecQ
family members contain three highly conserved domains - the core helicase domain, a RecQ-Cterminal (RQC) domain, and a helicase and RNase-D like C-terminal (HRDC) domain (Figure
1.1) [4, 14].
The core helicase domain
This domain is the most conserved and is a DEAD/H motif region containing seven
conserved helicase motifs (I, Ia, II, III, IV, V and VI) critical for ATP hydrolysis and is termed
the core helicase or ATPase domain [11, 28-30]. Apart from the seven helicase motifs, the RecQ
core helicase contains an additional characteristic sequence located upstream of motif I, referred
to as motif 0 [31]. This motif has been shown to be involved in DNA binding and required for
helicase activity [32-34]. Crystal structure determination has revealed that the core helicase
2

domain of RecQ family members is bi-lobed with two RecA-like domains N- and C-terminal of
a cleft. ATP binding and hydrolysis is mediated by conserved Walker A and Walker B motifs
located in the first domain and other elements like an arginine finger located in the second
domain [35]. The cleft contains the conserved helicase motifs to function as the putative DNA
binding region [2, 36-39]. Mutations within the core helicase domain have been shown to have a
deleterious impact, highlighting the functional significance of this domain [15, 32-34, 40, 41].
The RecQ C-terminal domain
RQC is the second conserved domain within all and unique to RecQ family members,
although its presence is debated in RecQ4 [42-44]. This domain is divided into two subdomains
– the zinc binding (Zn) and winged helix (WH) domain. The Zn domain coordinates a single
Zn2+ using four cysteine residues and two anti-parallel α-helices. Barring minor differences in the
length of α-helices in a few members, the Zn domain has been shown to be structurally similar
[36, 39]. Missense mutations in this domain have been implicated in a functional role in
maintaining protein stability, DNA binding as well as contributing to helicase activity [33, 41,
45-49]. BLM truncations containing only the ATPase domain and the Zn-binding domain have
been shown to perform helicase functions [50]. Although RecQ4 is regarded as lacking the
characteristic RQC domain, it has been shown to contain a novel domain featuring a Zn binding
region suggesting a different helicase mechanism compared to other human RecQs [44]. These
not only indicate the importance of the Zn binding domain, but also signify the functional
versatility of RecQ helicases.
While the WH domain is conserved structurally, the sequences have a poor similarity
with considerable charge variation within the RecQ family. The structural uniformity is
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characterized by the presence of a helix-turn-helix fold [36, 39]. Additionally, E. coli RecQ, and
human RecQ1, WRN and BLM contain a β-hairpin loop within the WH domain. Mutation
analyses suggest that this loop in E. coli RecQ, and human RecQ1, and WRN participates in
DNA unwinding, functioning as a strand separation pin [38, 39, 51-53]. There is also evidence
for the WH domain’s involvement in mediating interaction with DNA. Studies have shown that
the WH domain in E. coli RecQ, human RecQ1, WRN and BLM can recognize and bind to a
variety of DNA structures like double stranded DNA (dsDNA), G-quadruplexes (G4), and
double Holliday junctions (dHJs) [53-55]. Resolved crystal structures of Cronobacter sakazakii
RecQ, RecQ1, and BLM show that the WH domain location varies between different structures,
indicating that it is a mobile domain [2, 36, 52, 53].
The helicase and RNase D–like C-terminal domain
The third conserved domain within RecQ helicases is a distal C-terminal region
resembling the RNaseD C-terminal region, thus known as the HRDC domain. It is the least
conserved structural domain and among human RecQ helicases, present only in BLM and WRN
[56]. Crystallographic and biochemical analysis suggests that it plays an important role in
structure-specific substrate recognition and functionally differentiating the various RecQ family
members [57, 58]. Isolation of various HRDC domains has shown that the core structure is
conserved [57-60]. However, the primary sequences as well as surface charges of the HRDC
domains are very variable. The HRDC domain of the Saccharomyces cerevisiae RecQ family
member Sgs1 contains a patch of basic amino acid residues, making the predominantly
electropositive surface amenable for DNA binding [60]. The E. coli RecQ also has an
electropositive surface, but located on a different face of the HRDC domain [57]. While the
isolated Sgs1 HRDC domain can interact with single stranded DNA (ssDNA) and partial
4

dsDNA, E. coli RecQ binds preferentially to ssDNA [57, 60]. On the other hand, the WRN
HRDC domain does not have an electropositive surface and has been shown to not interact with
DNA in vitro [58]. Instead, the WRN HRDC domain has been suggested to play a role in protein
interactions [55, 58]. Although the BLM HRDC domain has not been isolated yet, studies using
solution structures show a weak affinity to ssDNA [61, 62]. While the HRDC domains of E. coli
RecQ and Sgs1 are dispensable for helicase function, they are required for stable dsDNA binding
[31, 63, 64]. A BLM mutant missing the HRDC domain displayed only a minor loss of helicase
activity, but had a far greater inability to disrupt dHJs as well as an inability to promote DNA
strand annealing [45, 65, 66]. A single amino acid residue change within BLM HRDC also
shows that it is required to dissolve dHJs [65, 67].
Taken together, the differing β-hairpin loop lengths within the Zn domain, the variable
sequence/charge distribution as well as relative mobility of the WH domain, and the role of the
HRDC domain in structure-specific DNA recognition indicate the important roles these unique
domains plays in conferring substrate specificity to the various RecQ helicases. A comparison of
helicase activities and substrate specificities of the human RecQ helicases has been provided in
Table 1.1 [3, 34, 68-76].
Non-conserved and unique domains
Unique and non-conserved domains flank the conserved domains described above.
Notably, WRN contains a unique N-terminal exonuclease domain which functions in protecting
and restarting stalled replication forks resulting from DNA damage [55, 77]. The human RecQs
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Figure 1.1. Schematic showing domain organization of selected RecQ helicases
Selected RecQ members are aligned according to the helicase domain. The Zn binding and WH
domains constitute the RQC domain. In RecQ4, the RQC domain is denoted as putative since its
presence has not been shown conclusively. The β isoform of RECQ5, the largest of at least three
splice variants known to express, has been used for this alignment. The domain lengths are
estimated and not accurately to scale. Adapted and modified from Vindigni & Hickson (2009)
and Croteau et al (2014) [3, 4].
6

contain a nuclear localization signal (NLS) at the extreme end of the C-terminal region with the
exception of RecQ4, which contains the NLS within the N-terminal region [78-81].
Table 1.1. Substrate specificity and helicase activities of human RecQ helicases
Relative Helicase Activity a
Substrate

RecQ1

BLM

WRN

RecQ4 b

RecQ5

-

-

-

+/-

ND

++

+

+

+

+

++

~/-

~/-

ND

ND

+

+

+

-

-

~/-

+

+++

-

-

-

+++

+++

-

-

+

+++

+++

-

~

-

+

+

ND

ND

Duplex

Forked duplex

3’-tailed duplex

D-loop

Bubble

G-quadruplex

Holliday junction

DNA/RNA hybrid
+, weak; ++, moderate; +++, strong; -, no activity; ~/-, partial activity; ND, not determined.
a
Data in this table is from the following studies: [3, 34, 68-76].
b
Data for RecQ4 is in the absence of ssDNA.
This table has been adapted from Croteau, et al (2014), Cheok et al (2005), and Sidorova &
Monnat Jr (2014) [82, 83].
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Human diseases resulting from RecQ helicase deficiencies
The human RecQ helicases function in DNA replication, repair, and recombination and
are therefore instrumental in maintaining genomic stability [3, 21, 25-27, 84, 85]. While all
RecQ helicases play important roles in maintaining a stable genome, defects in RECQL4, WRN,
and BLM lead to disease syndromes in humans [3, 9].
Rothmund-Thomson syndrome is caused by mutations in RECQL4
Defective RECQL4 has been linked to three disorders — Rothmund-Thomson syndrome
(RTS), RAPADILINO syndrome, and Baller-Gerold syndrome (BGS) [86, 87]. RTS is
characterized by sun-sensitive, poikilodermatous rashes from infancy. Other RTS features used
in clinical diagnosis include predisposition to osteosarcomas among other malignancies, juvenile
cataracts, defects in radial ray, alopecia, and loss of eyebrows and eyelashes [87, 88]. Many
individuals with RTS have a short stature along with bone abnormalities [88, 89]. At the cellular
level, RTS is characterized by hypersensitivity to ionizing radiation and reduced DNA repair
efficiency upon UV exposure [90-92]. The gene mutated in RTS is RECQL4 [93, 94]. Mutations
such as frameshifts, nonsense mutations, splice mutations, and intronic deletions predicted to
result in a truncated RECQL4 protein have been found in RTS patients [95]. Multiple short
introns within RECQL4 gene might be a reason for mis-spliced RECQL4 mRNA [96].
Furthermore, eight missense mutations clustered in the helicase region have been identified in
RTS patients [95].
Werner syndrome is caused by defects in WRN
Werner syndrome (WS) is the result of defects in the WRN gene. A broad spectrum of
mutations within WRN, including frameshifts, nonsense mutations, and splice mutations, has
8

been identified in WS patients. However, no missense mutations in WRN have been identified in
WS patients [84, 86]. WS patients exhibit progeroid features beginning at puberty, including
premature graying and hair loss, cataracts, type II diabetes, hypogonadism, atherosclerosis,
osteoporosis, along with increased sarcomas [97]. The cellular phenotype of WS cells includes
increased rate of somatic mutations, chromosome loss and deletions [98, 99]. The S-phase is
prolonged in WS cells with a reduction in both initiation frequencies and replicative life span
[100]. WS cells are mildly sensitive to ionizing radiation, and hypersensitive to DNA interstrand
cross-link-inducing agents and topoisomerase inhibitors [97].
BLM deficiency causes Bloom syndrome
BLM deficiency causes Bloom syndrome (BS), which will be described in detail in the
following section.
BLOOM SYNDROME
Clinical features of Bloom syndrome
BS is an autosomal recessive disorder first described as a unique human disease
syndrome in children with erythema and short stature by a dermatologist, David Bloom [101103]. Thereafter, James German observed that BS patients exhibited increased chromosomal
breakage and an elevated predisposition to cancer from a young age [103, 104]. The early
predisposition to a wide range of cancers remains the most common feature of BS, occurring at
greater frequency compared to the general population and is the most common cause of the
reduced life expectancy of ~27 years [105, 106]. Additionally, ~10-fold higher than normal rates
of crossovers between sister chromatids or sister chromatid exchanges (SCEs) were observed in
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cells from BS patients, and it remains the hallmark and only clinical diagnostic feature of BS
[107-110].
Other clinical features used as recognizable patterns in BS patients include growth
defects impacting height and weight, long and narrow face, prominent ears/nose, and a smaller
head circumference [102, 103, 108]. However, these features are variable and all BS patients
may not exhibit these features. Prenatal onset of growth deficiencies has been observed, with the
affected fetus being smaller for the gestational age. Children with BS exhibit malnourishment
and significant wasting [106, 111]. These deficiencies are life-long and BS patients are smaller
than the general population [112]. There have been reports of children with BS undergoing
growth hormone therapy. However, this has been proposed to be contra-indicated since hormone
therapy carries a potential risk of cancer and BS patients are predisposed to cancers [113].
Apart from growth deficiencies, additional endocrine dysfunctions in BS patients include
hypothyroidism, increased insulin resistance, glucose tolerance and susceptibility to early onset
type-2 diabetes mellitus (T2DM) [112].
Problems with feeding in infants and children are another clinical description used in BS
diagnosis. Slow feeding, disinterest in food, and gastroesophageal reflux (GER) have been
reported as typical issues faced by children with BS [106, 111]. This has been compounded by
obesity in some BS patients prescribed with a high caloric density formula and growth
supplements [112].
BS patients typically have normal skin at birth, which progressively goes on to present
dermatological complications. One of the first identified clinical BS presentations, facial rashes
form a typical butterfly-like pattern and have been described as poikiloderma in some individuals
10

[114]. Apart from erythema, unusual skin manifestations in BS patients include fissures, blisters,
and sudden loss of eyebrow and eyelash hair [115, 116]. Multiple forms of skin cancer have been
reported in ~10% of the 226 malignancies in 145 BS patients diagnosed at a mean age of 31.5
[117].
Infections of the upper respiratory and gastrointestinal tracts with no consistent causative
pathogen have suggested an impaired immune function in BS patients [102, 103]. Decreased
levels of one or more serum immunoglobulins classes have also been observed in BS patients
who have had evaluations of their immune system [112, 118]. Though they usually have normal
T- and B-cells with no defects in counts, various abnormalities in their functions and lineage in
BS patients have been observed and point to an impaired adaptive immune system [102]. Serious
pulmonary complication related deaths have been reported in individuals with BS, with treatment
unable to stop acute respiratory failure in one individual [105, 119, 120]. It has been proposed
that possible immunodeficiency and recurrent respiratory infections during childhood lead to
chronic lung disease, making it a significant cause of early mortality in BS patients [119, 120].
Impaired fertility is another characteristic feature of some BS patients, with males
invariably being infertile and some females undergoing delayed puberty as well as entering
menopause prematurely [103, 121, 122].
Cellular defects of Bloom syndrome
Apart from the characteristically elevated SCE levels, BS cells exhibit various other
chromosomal aberrations such as a significant increase in chromatid breaks and the presence of
quadriradial chromosomes, which suggest illegitimate inter-chromosomal recombination events
[107, 123-125]. Replication timing of early- as well as late-replicating loci is abnormal in BS
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cells and is accompanied by a constitutive increase in the appearance of DNA damage sites
[126]. The replication fork progression rate is reduced in BS cells along, with fork pausing
observed at an increased frequency and endogenous activation of DNA double-strand break
(DSB) checkpoint response [127]. Thus, not surprisingly, BS cells are hypersensitive to
genotoxic and replication stress inducing agents like hydroxyurea (HU). In response to such
stress, replication fork reactivation is compromised and cell division is delayed [128].
Recruitment of DNA damage response (DDR) factors like BRCA1, 53BP1 and the MRN
complex to stalled replication forks is delayed in BS cells [129, 130]. Consequently, stalled
replication forks accumulate with less than 40% of them being restarted and potentially cause
unscheduled origin firing leading to genomic instability [131]. In the absence of appropriate
replication restart, DNA DSBs develop and lead to extensive apoptosis of BS cells [129].
DNA/RNA hybrids known as R-loops have been observed to accumulate in BS cells [132].
Additionally, increased oxidative stress and mitochondrial abnormalities have been reported in
BS cells [133-136].
MUTATIONS AND POLYMORPHISM IN THE BLM GENE
Homozygosity and linkage disequilibrium studies identified chromosome 15, specifically
a locus within 15q26.1, as the genetic locus mutated in BS [137-140]. Approximately 20% of BS
patients have a small population of venous lymphocytes which display normal levels of SCEs as
opposed to the high SCE levels observed otherwise [141]. Somatic hybridization between low
SCE lymphocytes and high SCE cells led to the identification of a single gene responsible for
high SCEs in BS patient cells, the BLM gene [142].
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Bloom syndrome causing mutations
BS was observed to be more frequent in the Ashkenazi Jewish population compared to
any other population examined, estimated to be around 1/48,000 [143]. A homozygous 6-bp
deletion and 7-bp insertion was found in BLM from four BS patients of Ashkenazi Jewish
ancestry and is referred to as the blmAsh mutation [139]. Initial studies found this to be the most
common BLM mutation, with 26/28 of BS patients with both parents being Ashkenazi Jewish
found to be homozygous for the blmAsh mutation. 97% of chromosomes in BS patients with at
least one Ashkenazi Jewish parent carried the blmAsh mutation [144]. The carrier frequency for
this mutation is estimated to be between 1/110-1/45 within Ashkenazi Jewish populations across
various geographic locations [145-148]. The blmAsh mutation was also found in 5/91 unrelated,
non-Ashkenazi Jewish BS patients, who were all from Christian families of Spanish ancestry
from southwestern United States, Mexico, or El Salvador [144].
Apart from this founder mutation, various recurrent and unique mutations in BLM have
been identified in other populations as well. In a survey of 134 BS patients, 64 mutations in BLM
were identified in 125 individuals, with 54 of them causing premature termination of protein and
10 being missense mutations [149]. BS causing mutations within BLM encompass missense
mutations resulting in single amino-acid substitutions, frameshifts, splice-site mutations and
nonsense mutations [1, 149-153].
Heterozygosity in BLM and cancer risk
Reports from various studies indicate an uncertain association between heterozygosity for
pathogenic BLM mutations and cancer risk [145, 154-164]. Crossing mice heterozygous for the
BlmCin/+ null mutation with mice carrying a mutated Apc tumor suppressor gene resulted in
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earlier development as well as double the number of lymphoma compared to wildtype mice
[154]. This suggests that heterozygosity for genome stability maintenance genes could have a
potential association with increased cancer risk [154]. This was tested in a study comparing the
frequency of the founder mutation blmAsh in Ashkenazic populations to the frequency in
controls and it was found that 1/54 Ashkenazi Jewish individuals with colorectal cancer carried
blmAsh as opposed to 1/118 in the control group [145]. However, other studies report no
significant increase in the prevalence of colorectal cancer among blmAsh carriers compared to
controls [155-158]. A founder nonsense BLM mutation in Slavic populations (Gln548*) was
found to occur more frequently in those with a family history of breast cancer, apart from also
being associated with an increased risk of breast cancer development [159, 160]. Conversely, the
same mutation was found to have no positive association with either prostate or ovarian cancers
[161, 162]. A study using whole exome sequencing to screen breast cancer families identified
mutations in BLM in 2/438 breast cancer families compared to none in either healthy controls or
the 1000Genomes Project data [165, 166]. A recent study using molecular inversion probes for
targeted sequencing screened colorectal cancer patients and identified deleterious mutations in
BLM in 1.6 % of the patients compared to 0.2% in the control group [167].
One challenge with faced by these studies investigating cancer risk of BLM
heterozygosity was their low power. Additionally, it is unclear if mutations in BLM are solely
responsible for any associated risk or if other mutations contribute as well. These need to be
addressed in order to establish meaningful cancer association with heterozygosity in BLM in
otherwise unaffected populations.
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Polymorphism in BLM and disease risk
Single nucleotide polymorphisms (SNPs) in BLM have been reported to be associated
with susceptibility to breast cancer, bladder cancer, malignant melanoma, acute myeloid
lymphoma, and myelodysplastic syndromes [168, 169]. These are non-coding SNPs and there is
no evidence of linking them to SNPs in BLM exons. Among nonsynonymous SNPs in BLM for
which allelic frequencies are known, only three alleles (V1190I, P868L/R, and V1321I) are not
rare with a minor allele frequency >0.05 [170, 171]. An analysis of the association between rare
SNPs and risk of common disease found that rare SNPs have a higher likelihood of being
functional with a stronger effect size compared to common SNPs. Combined with the rarity of
SNPs in the human genome, it is proposed that rare SNPs are a critical genetic basis of common
human diseases [172]. And since almost all nonsynonymous SNPs in BLM are rare (with an
allele frequency <0.05), they are prime candidates for functional characterization as the first step
in determining risk-association.
Functional relevance of coding SNPs in BLM
So far, 74 SNPs in BLM resulting in coding variants of uncertain clinical significance
have been identified [171, 173, 174]. A comprehensive functional evaluation of coding BLM
variants was undertaken in an earlier study using a humanized yeast model [40]. S. cerevisiae
cells expressing a chimera consisting of the disordered N-terminal half of Sgs1 and C-terminal
half of BLM were used to perform complementation assays to identify functional significance of
various coding BLM variants. 41 missense and 2 rare variants contained in the BLM C-terminal
region in the chimera were ranked for their probability to impair BLM function. Eventually, 27
variants ranging from the highest to lowest probability to impair BLM function were chosen for
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functional evaluation. This analysis identified nine new BLM variants not currently associated
with BS which are candidates for adding to the list of thirteen currently known BS causing
missense mutations. Furthermore, these deleterious mutations in BLM not yet associated with BS
were characterized in human cells expressing full length BLM variants and led to the
identification of 5 candidates for new BS causing mutations and 3 hypomorphic alleles, which
may have a cancer predisposition role or confer BS-like symptoms [15]. Five of these BLM
variants exhibit functional defects similar to known BS causing missense mutants, which
suggests that they have the potential to cause BS in a homozygous state or in a compound
heterozygous state with any known BS causing mutation. Three other BLM variants appeared to
be only partially defective, with P868L being the most common and occurring at a frequency of
0.051 in the general population [170, 171, 173]. Based on its allele frequency, approximately 1 in
10 individuals are carriers and 1 in 380 individuals are predicted to be homozygous for P868L.
This number far exceeds the number BS cases, indicating that P868L is not associated with BS.
However, the functional analysis of P868L revealed at least a partial loss of function, which
suggests that a considerable number of individuals lack a fully functional BLM allele and might
an increased cancer predisposition [15, 40]. The association of P868L with increased colorectal
cancer and its partially impaired function support this possibility [15, 175].
These findings have significant implications for the role of mutations and polymorphism
in the BLM gene beyond BS. Conventionally, biallelic mutations in caretaker genes have been
regarded as being relevant to cancers [176]. These studies provide evidence that biallelic
alterations in BLM not leading to BS might still be associated with a higher risk for cancer
development compared to the general population. Furthermore, hypomorphic BLM alleles could
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be impaired in response to genomic stress in otherwise asymptomatic individuals and potentiate
genome instability.
STRUCTURE OF THE BLM HELICASE
The BLM C-terminal region contains the helicase core
The product of the BLM gene is the BLM helicase, which unwinds DNA with a
3’→5’polarity [41, 177]. BLM is a 1,417 amino acid polypeptide. The helicase core stretching
from residues 640-1290 is its best characterized structure and contains structural domains
characteristic of the RecQ helicase family (Figure 1.5) [45]. The two RecA-like ATPase domains
are located within residues 640-857 and 858-993 respectively, and contain the conserved
helicase motifs (0, I, Ia, II, III, IV, V and VI) [2]. This domain is critical for ATP hydrolysis [1,
2, 32, 50].
Downstream from the core helicase is the RQC domain containing the Zn binding
(residues 994-1068) and WH (residues 1069-1192) sub-domains [2, 37]. Structural and
functional characterization of the Zn binding domain have revealed that it plays important roles
in the ATPase and helicase catalytic activities of BLM, apart from being implicated in
maintaining protein stability. Mutating the cysteines involved in coordinating the Zn2+ ion
further determined that while it is not important for ATP binding, duplex DNA binding was
reduced and G4 DNA binding was completely abrogated [178]. Moreover, missense mutations
affecting residues C1036 and C1055 in the Zn binding domain being found in BS patients
underscores its importance in BLM function [41]. A co-crystal structure of BLM 640-1291 in
complex with a 3’-overhang duplex DNA has shown that BLM RQC binds to dsDNA using a
binding mode similar to other RecQ proteins WRN and RECQ1 [179]. However, the BLM RQC
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domain can be structurally differentiated from the RQC of WRN and RECQ1 [37, 180]. Two βstrands form a prominent β-hairpin structure in the BLM WH domain, which is thought to
function as the DNA strand separation pin found in other RecQ helicases [37-39, 42, 51].
Notably, the aromatic residue at the tip of this β-hairpin in the BLM WH is missing and instead
features acidic residues forming an extensive polar interface with dsDNA [2]. This suggests that
the BLM WH plays a structural role in DNA strand separation despite the dissimilar sequence
and is involved in substrate specificity. Unique to BLM among human RecQ helicases, an
insertion between the α1- and α2-helices of the WH domain forms a loop perpendicular to the βhairpin and plays a role in binding dHJs [180]. Another loop structure extends from the Cterminal region of WH domain and is proposed to be involved in positioning the HRDC domain
[180]. A co-crystal structure has also revealed that upon WH binding dsDNA, a lysine rich loop
(868PKKPKK873) outside WH becomes available as another interaction site by connecting the
first β-strand of the WH domain to the α-1 of the C-terminal lobe of the ATPase domain [2].
Overall, the WH has an important role in DNA binding.
The HRDC domain is unique to BLM and WRN among human RecQ helicases [2, 4, 56].
The least conserved among the three characteristic RecQ helicase domains, the BLM HRDC is
predominantly electronegative [62]. This domain has been shown to confer substrate specificity
and, while dispensable for dsDNA binding, is critical for dHJ binding and dissolution [65]. The
HRDC domain (residues 1193–1290) is C-terminal of the WH domain, separated by an extended
linker rich in lysine (residues 1199–1208) which creates a gap in the surface by pushing it away
from the rest of protein [2]. Significantly, a co-crystal structure indicates that the HRDC domain
is in a position to form an intramolecular association with the C-terminal ATPase domain and
exhibits a weak binding affinity in solution studies in the presence of ATP. Enzymatic
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characterization of BLM mutants that interrupted this HRDC-ATPase domain interaction
indicated a slightly reduced ATPase activity and dHJ dissolution efficiency [2]. Furthermore,
BLM mutants lacking the entire HRDC domain showed reduced helicase activity and less
efficient coupling of ATP hydrolysis to DNA unwinding [179]. Put together, these data point to
the involvement of the HRDC domain in BLM catalytic function.
Similar to other human RecQ proteins, BLM has a nuclear localization signal sequence
(NLS) C-terminal of the conserved RecQ helicase domains located between residues 1134-1357
[78, 79, 181-183].
The BLM N-terminal region is predicted to be intrinsically disordered and forms a
major site for protein interactions
In contrast to the highly conserved and structured C-terminal region, the BLM N-terminal
tail spanning residues 1-639 is poorly conserved at the amino acid level and predicted to be
intrinsically disordered (Figure 1.2). Therefore, the crystallographic and mutational analyses
which delineated functional domains in the C-terminal region could not be applied to identify the
functions of the BLM N-terminal tail. Sgs1, the S. cerevisiae ortholog of BLM, has served as a
model to understand the BLM N-terminus and predictions show that the property of disorder is
conserved between BLM and Sgs1 [184]. Moreover, the N-terminal regions of various RecQ
helicases have been shown to be involved in protein interactions and are therefore biologically
relevant [4, 26]. Similarly, BLM N-terminus forms a platform for various protein interactions
and regulates BLM activity [185-192].
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Figure 1.2. Structure of the BLM helicase
A) IUPRED prediction of disordered BLM N-terminal region and map of the conserved Cterminal domains. BLM catalytic core has been magnified to show the location of BS causing
missense mutations. B) Structure of BLM with bound Zn ion and ADP depicted as spheres.
Adapted from [1, 2]. BLM structure graphic created using PyMol [12].
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INTERACTIONS AND FUNCTIONS OF BLM
BLM functionally interacts with numerous proteins via both the N- and C-terminal
regions to participate in DNA repair, recombination and replication pathways to preserve
genomic stability. Known interactions and functions of BLM are summarized in Figure 1.5 and
Table 1.2.
Canonical role of BLM in recombinational DNA repair
The best understood function of BLM is in dissolving dHJs during homologous
recombination (HR) mediated DNA double strand break repair (DSBR) (Figure 1.3) [67, 193].
When a homologous template is available, the 5’-end of DNA DSBs can be resected to generate
a 3’-overhang in a key early step determining repair pathway choice [194]. End resection is
initiated by the MRE11 as part of the MRE11-RAD50-NBS1 (MRN) complex along with its
cofactor CtIP [195]. End resection is further accelerated by recruitment of BLM to DSB ends by
MRN. BLM plays a role in long range resection catalyzed either by DNA2 or the 5′ to 3′
exonuclease EXO1 [196, 197]. BLM physically interacts with DNA2 to promote DNA end
resection in an ATP-dependent manner, where BLM unwinds DNA to enable the nuclease
functions of DNA2 [198]. The single strand DNA (ssDNA) binding protein RPA interacts with
BLM and enhances end resection at DSBs by stimulating BLM helicase activity and stabilizing
the nascent 3’-overhang [188, 189, 199]. The MRN cofactor CtIP also physically interacts with
BLM, enhancing long range resection by possibly stimulating BLM/DNA2 activity after MRN
induced nick [200]. Alternatively, it is proposed that EXO1 promotes further resection upon
stimulation of its nuclease activity by BLM, MRN, and RPA [197, 201]. Unlike DNA2,
stimulation of EXO1 mediated end resection does not require BLM helicase activity and instead
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depends on a physical interaction between the two to increase EXO1 affinity to DSB ends [197,
201]. Thus, BLM is an important part of two DSB end resection machineries —
BLM/DNA2/RPA/MRN and EXO1/BLM/RPA/MRN [197].
The resultant processed ends form substrates for the HR-mediated DSBR pathway.
Rad51 displaces RPA from the nascent 3’-overhangs to form nucleoprotein filaments which
invade homologous duplex, form the intermediate D-loop structure and initiate the search for
sequence homology [202]. This is a defining step committing to the HR pathway. The intact
homologous sequence is used as a template by the invading strand for DNA synthesis and the Dloop forms dHJs when the second processed end is captured. The dHJs form the substrate for the
structure specific BTR complex comprising BLM, TopoIIIα and RMI1/RMI2 [203-206]. Using a
mechanism distinct from Holliday junction resolution, the BTR complex resolves dHJ structures
without resulting in exchange of sequences flanking the intermediate structure. This mechanism
is termed dissolution and the complex is known as the BTR dissolvasome [67, 206]. The dHJs
are dissolved by branch migration of the two Holliday junctions towards each other until a
hemicatenated intermediate is formed, which is then decatenated. Within the complex, BLM is
the catalytic component driving branch migration. Once the dHJs fuse to form the hemicatenated
intermediate, TopoIIIα drives the decatenation to topologically separate the two duplexes
resulting in dHJ dissolution. Furthermore, BLM ATPase activity is required for the decatenation
step [67, 207, 208]. While RMI1 and RMI2 interact with BLM and TopoIIIα to stimulate the
dissolution reaction, it is also speculated that they help with DNA binding via putative OB fold
domains [205, 209, 210]. The products of dHJ dissolution are always non-crossover. Conversely,
resolution of dHJs by resolvases can yield either crossover or non-crossover products.
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Figure 1.3. BLM functions in HR-mediated DNA double-strand break repair
Diagrammatic models showing BLM functions at key steps of DSBR repair pathway. BLM
participates in the initial end resection as part of either BLM/DNA2/RPA/MRN or
EXO1/BLM/RPA/MRN machineries. Post second-end capture, BLM mediates dissolution of
dHJs as part of the BTR dissolvasome. Conversely, BLM can mediate strand displacement to
initiate the SDSA pathway of DSBR. All BLM functions in DSBR always result in the formation
of non-crossover products. Adapted from Maloisel et al (2008) [16].
BLM physically interacts with Rad51 and plays a regulatory role within the HR-mediated
DSBR pathway [211-213]. BLM can play an anti-recombinogenic role by displacing Rad51 to
prevent nucleoprotein filament formation, inhibiting strand invasion, and further disrupting
nascent D-loops [214-216]. DSBR proceeds via the synthesis-dependent strand annealing
(SDSA) HR pathway after the invading strand displacement and D-loop disruption by BLM,
resulting in non-crossover products. It has been shown that BLM promotes Rad51 mediated
strand invasion by ATP-bound RAD51 filaments, but inhibits inactive ADP-bound Rad51
filament invasion [217]. By playing a pro- and anti-recombinogenic role during this step in HR,
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BLM potentially suppresses illegitimate recombination events. Moreover, it is evident that HR
mediated DSBR in the presence of BLM predominantly results in non-crossover products. With
evidence suggesting that HR-mediated DSBR is major pathway involved in repairing
chromosomal DNA DSBs, the function of BLM in this pathway to predominantly yield noncrossover products is very significant [218]. Illegitimate mitotic recombination product
formation when collapsed replication forks undergo DSBR might be an explanation for the high
SCE levels in BS cells.
BLM functions in response to DNA replication stress
Defective replication stress response in BS cells led to investigations into the possible
functions of BLM in rescuing replication forks. Indeed, studies have shown that BLM localizes
to stalled replication forks which develop into DSBs [129]. BLM is necessary for timely
recruitment and functions of DDR factors like BRCA1, NBS1, and 53BP1 to DSBs, providing
further evidence of BLM being associated with facilitating replication fork protection [129, 130].
Furthermore, BLM is required for efficient replication restart in response to replication stress
[131, 219, 220]. BLM can promote replication fork restart through its function in HR-mediated
DSBR pathway [221]. Given its structural affinity to replication and recombination
intermediates, it has been proposed that BLM can mediate the formation of favorable DNA
structures to restart forks stalled by lesions on the leading strand. In vitro analyses have shown
that BLM can promote regression of model replication forks by creating a “chicken foot”
structure in which the newly synthesized leading and lagging strands are annealed [222, 223].
BLM-mediated replication fork regression allows the leading strand to bypass the lesion by
template switching. Following lesion bypass, replication can restart either by reversal of the
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regressed fork regression by BLM-mediated branch migration or an HR-mediated pathway
dependent on dHJ dissolution by BTR (Figure 1.4) [223].

Figure 1.4. BLM-mediated replication fork restart
Replication forks can stall due to lesions on the leading strand during DNA replication. BLM
mediates regression of the stalled fork via template switching to bypass the lesion. BLM may
reverse the regressed fork to facilitate replication restart. Conversely, the regressed arm can
invade the parental chromosome, generating a dHJ which can be dissolved by BLM as part of the
BTR dissolvasome.
BLM also associates with Fanconi anemia (FA) proteins to play important roles in
replication restart [224-226]. FANCM is thought to bind to RMI1/RMI2 and recruit the BTR
complex to sites of damage [224, 227]. Notably, BLM physically interacts with the 5’ to 3’
helicase FANCJ and thought to cooperate during replication restart [228, 229]. FANCD2 is also
thought to mediate phosphorylation of the BTR complex in response to DNA damage, promote
replication fork restart, and suppress unscheduled firing of new replication origins [230, 231].
BLM physically interacts with and recruits p53 to Rad51 sites at stalled replication forks
[232]. The BLM-p53 interaction at Rad51 sites is proposed to regulate the HR pathway and
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suppress excessive recombination by either inhibiting Rad51 activity or inhibiting BLMmediated inhibition of Rad51 activity.
In response to replication stress, BLM also interacts with the DDR protein 53BP1 [233235]. Phosphorylation of both 53BP1 and BLM (on residue T99) enhances their binding and colocalization with Rad51 at DSB sites. Interactions between these three proteins have been shown
to have an antirecombinogenic role during HR-mediated DSBR after replication stress induction
[234].
BLM interacts with TopBP1, an important hub for protein interactions during DNA
replication stress response, and evidence suggests that this interaction is necessary to suppress
SCEs and unscheduled origin firing [186, 236]. The regulation of BLM protein levels by
TopBP1 is a debated role [89, 186].
BLM was identified as a member of the BRCA1-associated genome surveillance
complex (BASC) along with BRCA1, MSH2, MSH6, MLH1, ATM and the MRN complex
[237]. BRCA1, BLM, and the MRN complex have been shown to colocalize to putative DNA
DSB sites after replication stress. All members of this complex can recognize and bind noncanonical DNA structures, leading to suggestions that BASC is DNA damage sensor. The
interaction between BLM and MLH1 is not required for DNA mismatch repair, further indicating
a role in replication stress induced damage response [238].
BLM unwinds stable DNA structures that impede DNA replication
G4s are stable secondary DNA structures which cannot be easily unwound by the
replicative helicase and impede replication fork progression [239, 240]. G4 motifs are prevalent
and distributed throughout the genome, including a vast majority of replication origins and
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coding sequences [241]. BLM can recognize, bind, and unwind G4 structures in vitro and has
also been associated with a functional role in facilitating timely replisome movement by
unwinding G4 rich regions in vivo [68, 242, 243]. Further evidence of a role for BLM in
recognizing G4 structure is provided by the observation of SCEs being enriched at coding
regions, specifically sites containing G4 motifs, in the absence of BLM [244]. It is proposed that
BLM suppresses recombination at G4 structures in transcribed regions and protects genomic
integrity. Recently, BLM interaction with WRN and RPA facilitated by HERC2 has been shown
to be important for suppressing G4 structures [192].
BLM can unfold 3′-ssDNA tails containing G4 motifs using a mechanism involving three
discrete steps to mediate unidirectional translocation [245]. It can repeatedly unfold G4
structures containing connected dsDNA and ssDNA by remaining anchored to the ss/dsDNA
junction. Lastly, BLM can also unfold G4 structures by spooling in ssDNA. This suggests that
BLM can potentially use a different mechanism to unfold G4 structures in different molecular
environments [245].
R-loops are DNA:RNA hybrids which cause replication fork stalling. Underscoring its
specificity to a variety of non-canonical DNA substrates, BLM can also unwind model R-loops
in vitro [246]. Observations of R-loop accumulation causing DNA damage in BS cells and
BLM/R-loop proximity in vivo seem to imply BLM involvement in maintaining replisome
stability at sites of collision with R-loops [132].
BLM functions in telomere replication and maintenance
G4 structures are the primary barriers the replisome encounters while replicating
telomeres [247]. There is evidence of increased telomeric G4 structures and slow moving
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replication forks originating within telomeres in BS cells, indicating a role for BLM in telomere
synthesis [248]. The shelterin component TRF1 physically interacts with BLM to facilitate
lagging strand synthesis during telomeric replication, where the template is the TTAGGG repeat
[249]. The BLM-TRF1 interaction potentially plays a role in unwinding the secondary structures
formed within these sequences. The predominant role of BLM in telomere maintenance appears
to be in the HR pathways in alternative lengthening of telomeres (ALT) cells during ALT‐
mediated telomere replication [250-252]. The BTR dissolvasome functions in ALT‐mediated
telomere synthesis possibly by processing recombination intermediates formed during strand
invasion, leading to POLD3‐dependent telomere synthesis and subsequent dissolution to prevent
exchange of telomeric DNA [251]. BLM, BRCA1 and FANCM are recruited to ALT telomeres
in response to replication stress in an interdependent manner [250]. In ALT cells lacking
FANCM, BLM and BRCA1 interact to initiate DNA end resection leading to HR-mediated
DSBR to counter replication stress [250]. BLM and BRCA1 interact during S- and G2-phases
and co-localize with RAD50 at telomeres in ALT cells [253]. In vitro assays using DNA
substrates resembling forked structure containing telomeric repeats suggests that BRCA1
enhances BLM unwinding activity [253]. Additionally, exposure to replication stress induces the
formation of late-replicating intermediates known as ultra-fine bridges (UFBs). BLM contributes
to telomere maintenance by dissolving these late-replicating intermediate structures [252].
BLM and ultrafine anaphase bridges
Distinct DNA structures linking two sister chromatids, termed anaphase bridges, can be
stained during mitosis. Subsequently, a subclass of anaphase bridges was classified as ultrafine
anaphase bridges (UFBs) [254, 255]. The BTR dissolvasome and the PLK1-interacting
checkpoint helicase (PICH) localize to these UFBs [255]. PICH specifically interacts with and
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recruits BLM while the localization of the rest of the BTR dissolvasome to UFBs depends on
BLM [255]. Most UFBs arise at centromeres, where the BTR dissolvasome and PICH potentially
associate with Topo IIα and promote centromere disjunction [256, 257]. Indeed, in vitro and in
vivo interactions between BLM and Topo IIα support this notion [258, 259]. FS-UFBs are a
different class found only at common fragile sites (CFS) and proposed to be the result of
incomplete DNA replication [259, 260]. In the face of replication fork stalling, additional
initiation occurs to complete DNA replication. But these initiations do not occur at CFS and
DNA replication is incomplete when mitosis begins, resulting in FS-UFBs [261]. It is proposed
that recruitment of FANCD2/FANCI to CFS in late S- and early G2-phase specifies FS-UFBs,
which are then coated by BLM and PICH. BLM also mediates FANCM localization to FS-UFBs.
FANCM is observed on FS-UFBs even after BLM dissociation, suggesting that BLM either
recruits FANCM to FS-UFBs or makes the FS-UFBs more accessible to FANCM [254]. UFBs
generated by HR constitute a third class of UFBs, termed HR-UFBs [262, 263]. HR-UFBs in
anaphase can be stained with PICH and BLM, and subsequently visualized as RPA-coated,
ssDNA bridges [263]. Lastly, BLM is also a part of a fourth class of telomeric UFBs or T-UFBs
induced by overexpressed TRF2 interfering with telomere the replication leading to
chromosomal end-on-end fusion [252, 263, 264]. Topo IIα inhibition has also been shown to
induce T-UFBs, suggesting that they consist of catenanes or replication intermediates [265].
Lack of UFB resolution could lead to DNA damage that can be repaired by the errorprone non-homologous end joining (NHEJ) pathway during the subsequent cell cycle. However,
this can potentially result in chromosomal aberrations. The cytogenetic features of BS and the
presence of BLM on UFBs further highlight the significance of BLM in maintaining genomic
stability.
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Table 1.2. Known BLM interacting partners and their functional significance
BLM Interactor

Metabolic Pathway

WRN, HERC2

G-quadruplex unwinding

EXO1, RAD51, RMI1, RMI2
RPA, Topo IIIα, DNA2, MRE11

Recombinational DNA repair

BRCA1, FANCJ, FANCD2, FANCM
H2AFX, MLH1, MSH2, MSH6, RAD50
TopBP1, p53, 53BP1, XRCC2, Mus81

Response to replication stress

TERF1, TERF2, BRCA1, FANCM

Telomere replication and maintenance

FANCD2, FANCI, FANCM, Topo IIα

UFB resolution

REGULATION OF BLM FUNCTION
Multiple studies have uncovered different modes of BLM regulation, particularly
mediated via posttranslational modifications (PTMs). These regulate BLM stability, cell cycle
specific expression, localization, and interactions.
Phosphorylation of BLM during the replication stress response
Apart from its functions in recombinational DNA repair, BLM also functions in intra Sphase checkpoint signaling in response to replication stress. This serves to pause the cell cycle,
inhibits replication origin firing, and mediates recruitment of DDR proteins to sites of DNA
damage [266]. BLM is phosphorylated by the checkpoint kinases ATM in response to ionizing
radiations and ATR in response to replication stress induced damage at residues T99 and T122
[131, 267, 268]. Replication restart is delayed without impacting BLM localization in the
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Figure 1.5. Known and putative functions of the BLM helicase
A summary of known and putative functions of BLM in DNA repair, recombination and
replication to maintain genomic stability.
absence of this phosphorylation, while phosphorylation at T99 enhances its localization with the
DSB markers γ-H2AX and 53BP1 [131, 234, 269]. BLM is also a substrate for constitutive
phosphorylation by Chk1 and Chk2 kinases at residue S646, which decreases upon DNA damage
and is thought to aid BLM localization to damage sites [233, 270].
Regulation of sub-cellular localization of BLM
BLM localizes to discrete sub-nuclear structures known as PML bodies (PML-NBs) in
the absence of DNA damage [271]. PML-NBs are associated with a role in damage sensing and
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also harbor other DDR factors like the MRN complex, Rad51/52, p53, TopBP1 and Topo IIIα
[272]. Significantly, all these factors are known BLM interactors. With its ability to associate
with the small ubiquitin-like modifier SUMO, it is thought that PML-NB interacting proteins
contain SUMO interacting motifs (SIM) and localize to SUMOylated PML-NBs [272].
Consistent with this, BLM contains two SIMs at residues 217-220 and 235-238 which have been
shown to be critical for its localization to PML-NBs [273]. Furthermore, BLM function in DNA
damage response is negatively regulated by SUMOylation at K317 and K337 [274]. Monoubiquitinated BLM also localizes to PML-NBs in an anti-recombinogenic mechanism which
suppresses excessive HR [275]. BLM is phosphorylated in the absence of DNA damage on S714
and T766 by Cdc2, which is thought to exclude it from chromatin binding without impacting its
ability to form the BTR complex [276, 277]. MPS1 phosphorylates BLM at S144, playing a role
in spindle assembly checkpoint (SAC) to ensure faithful segregation of chromosome [278].
Appropriate SAC function is critical in preventing chromosome loss and aneuploidy, and this
lack of this role of BLM might explain the chromosomal instability observed in BS cells.
PTMs regulate the pro- and anti-recombinogenic activities of BLM
It is speculated that phosphorylation by Chk1, Chk2 [233, 270] and MPS1 [276, 277]
which impact the recruitment of BLM to chromatin could be involved in regulating its role in the
end resection step of HR mediated DSBR. The phosphorylation of BLM at T99 is involved in
association with 53BP1 and RIF1 to suppress the CtIP/MRE11- initiated error-prone alternative
end-joining (A-EJ) repair pathway after the end resection step [279]. SUMOylation of BLM has
been shown to enhance interaction with Rad51, and might regulate the pro- and antirecombinogenic functions of BLM during the strand invasion step of the HR mediated DSBR
pathway [280]. The recruitment of BLM to stalled replication forks to perform an anti32

recombinogenic role in association with 53BP1 is regulated by poly-ubiquitination at K105,
K225, and K259 [232, 235].
Regulation of BLM by TopBP1 and MIB1
BLM expression levels are low in G1, peak during S phase and persist in G2 phase,
consistent with its known functions in the HR pathways [89, 276, 281]. It is suggested that the
E3 ubiquitin ligase MIB1 ubiquitinates BLM at residues K38 and K39/40 and targets for
proteasome mediated degradation in G1 [89]. On the other hand, phosphorylation of BLM at
S338 enhances its interaction with TopBP1 and stabilizes it [89]. BLM stabilization by TopBP1
binding appears to be debatable, with another study showing that phosphorylation of BLM at
S304 is necessary for TopBP1 interaction, while the interaction itself is not required for BLM
stability in S phase [186].
HYPOTHESES AND AIMS
Defects in BLM cause Bloom syndrome (BS) is an autosomal recessive disorder
characterized by subfertility, short stature and highly elevated predisposition to cancer.
Functional characterizations have identified deleterious as well as hypomorphic BLM alleles in a
humanized yeast model. Furthermore, SNPs in BLM have been found in human tumor samples.
We rank and functionally characterize nonsynonymous SNPs in the BLM coding region to
investigate their functional significance. We hypothesize that BLM contains additional riskassociated rare variations which might increase susceptibility to the disease, apart from an
increased cancer risk. BLM is an important replication stress response factor, functioning to
facilitate replication fork restart and suppress illegitimate recombination events to maintain
genomic stability. Most studies evaluating the role of BLM in replication have focused on its role
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in response to replication stress. And despite BS cells exhibiting a host of replication defects in
the absence of any exogenous stress, the current understanding of a role for BLM in an
unperturbed S phase is limited. BLM expression peaking in S phase and its affinity to a variety
of non-canonical DNA substrates suggest a role beyond replication stress response as well.
Identifying novel interactors of BLM in S phase is warranted to investigate its role in pathways
during unperturbed replication. Cell lines established from BS patients are aneuploid, with some
uncertainty regarding the nature of chromosomal instability and gene product dosage in such
cells. We generate and functionally characterize a diploid BLM knockout cell line and in
conjunction with its isogenic parental cell line perform a proteomic-based screen to identify
novel BLM interactors. Members of the RecQ helicase family have been shown to interact with
various components involved in replication associated pathways. We hypothesize that BLM
associates with similar components in an undisturbed S phase and assist in maintaining
replication fork progression. The following specific aims have been designed to test these
hypotheses:
AIM 1 (Chapter two): Assess the ability of uncharacterized BLM variants of uncertain
significance to complement cellular defects in BLM deficient human cells.
AIM 2 (Chapter three): Generate a diploid BLM knockout cell line using CRISPR/Cas9mediated genome engineering and characterize the cellular defects in DNA repair and the DNA
damage response.
AIM 3 (Chapter four): Determine the composition of the BLM complex in unperturbed S phase
and determine the functional significance of novel BLM interactions.
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CHAPTER TWO:
CELLULAR DEFECTS CAUSED BY HYPOMORPHIC VARIANTS OF THE BLOOM
SYNDROME HELICASE GENE BLM
Note to reader: This chapter has been previously published and is available under the terms of
the Creative Commons Attribution License from the publisher as Shastri, V. M. and Schmidt, K.
H. (2016), “Cellular defects caused by hypomorphic variants of the Bloom syndrome helicase
gene BLM”. Mol Genet Genomic Med, 4: 106-119. Research was designed by K. Schmidt and
all experiments were performed by V.M. Shastri. Corresponding author: Kristina Schmidt,
Department of Cell Biology, Microbiology and Molecular Biology, University of South Florida,
4202 E. Fowler Avenue, ISA2015, Tampa, FL 33620. Phone: (813) 974-1592. Fax: (813) 9741614.; E-mail: kschmidt@usf.edu
ABSTRACT
Background
Bloom syndrome is an autosomal recessive disorder characterized by extraordinary
cancer incidence early in life and an average life expectancy of ~27 years. Premature stop codons
in BLM, which encodes a DNA helicase that functions in DNA double‐strand‐break repair, make
up the vast majority of Bloom syndrome mutations, with only 13 single amino acid changes
identified in the syndrome. Sequencing projects have identified nearly one hundred single
nucleotide variants in BLM that cause amino acid changes of uncertain significance.
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Methods and results
Here, in addition to identifying five BLM variants incapable of complementing certain
defects of Bloom syndrome cells, making them candidates for new Bloom syndrome causing
mutations, we characterize a new class of BLM variants that cause some, but not all, cellular
defects of Bloom syndrome. We find elevated sister‐chromatid exchanges, a delayed DNA
damage response and inefficient DNA repair. Conversely, hydroxyurea sensitivity and
quadriradial chromosome accumulation, both characteristic of Bloom syndrome cells, are absent.
These intermediate variants affect sites in BLM that function in ATP hydrolysis and in
contacting double‐stranded DNA.
Conclusion
Allele frequency and cellular defects suggest candidates for new Bloom syndrome
causing mutations, and intermediate BLM variants that are hypomorphic which, instead of
causing Bloom syndrome, may increase a person's risk for cancer or possibly other Bloom‐
syndrome‐associated disorders, such as type‐2 diabetes.
INTRODUCTION
Bloom syndrome (MIM 210900 for BLM) is a rare chromosome breakage disorder
characterized by short stature and an extraordinary predisposition to a broad range of cancers,
often multiple, early in life (German and Passarge 1989; German and Ellis 1998). Other
symptoms that can be present in persons with Bloom syndrome include sun‐sensitive skin with
telangiectatic and hyper‐ and hypo‐pigmented areas, immunodeficiency, subfertility in females
and infertility in males, and type 2 diabetes mellitus (Bloom 1954; German and Passarge 1989;
German and Ellis 1998; Ellis et al. 2008).
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The gene defective in persons with Bloom syndrome – the tumor suppressor gene BLM –
encodes a 3′ to 5′ DNA helicase that belongs to the evolutionarily conserved RecQ helicase
family (Ellis et al. 1995; Bennett and Keck 2004). The helicase core of BLM spans amino acid
residues 658 to 1197 and consists of the DNA‐dependent ATPase (DEAH) domain with seven
conserved helicase motifs, and the RecQ‐C‐terminal (RQC) domain with Zn‐binding (Zn) and
winged‐helix (WH) subdomains (Hickson 2003; Bennett and Keck 2004). C‐terminal of the
RQC domain is the conserved Helicase and RNase D C‐terminal (HRDC) domain, which plays a
role in DNA binding and is thought to regulate helicase activity (Huber et al. 2006; Kim and
Choi 2010). The best understood roles for BLM are in the repair of DNA double strand breaks
(DSBs) by homologous recombination (HR) where – in a complex with topoisomerase Topo
IIIα and Rmi1/Rmi2 – BLM dissolves double Holliday junctions (dHJ) into noncrossover
products (Hickson 2003). BLM/Topo IIIα/Rmi1/Rmi2 has also been implicated in the processing
of the ends of DSBs into single‐strand 3′ overhangs for the strand invasion step of HR and in the
control of HR levels by reversing strand invasion events (Bachrati et al. 2006; Daley et al. 2014;
Sturzenegger et al. 2014). As a result, cells that lack functional BLM exhibit elevated levels of
mitotic recombination, chromatid breaks, increased crossover formation between sister
chromatids (~10‐fold higher in cells from persons with Bloom syndrome), and signs of
illegitimate interchromosomal recombination events suggested by the presence of quadriradial
chromosomes (Chaganti et al. 1974; Groden et al. 1990; Lonn et al. 1990; Groden and
German 1992). Consistent with the role of BLM in maintaining genome integrity, Bloom
syndrome cells are sensitive to genotoxic agents, including hydroxyurea (HU), which causes
replication stress by depleting the nucleotide pool, and camptothecin (CPT), a natural product
that interferes with replication and transcription by trapping topoisomerase I on nicked DNA.
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The elevated level of mitotic recombination between homologous chromosomes is thought be a
major contributor to the extraordinary cancer predisposition in Bloom syndrome as it can lead to
the loss of heterozygosity (LOH) at loci carrying tumor‐suppressor genes (Chester et al. 1998;
Traverso et al. 2003).
BLM is transcribed as a 97.93 kb pre‐messenger RNA, with 21 exons coding for a 1417
amino acid protein. In the majority of persons with Bloom syndrome the BLM gene is inactivated
by small insertion/deletion mutations or nonsense mutations that lead to a premature stop codon
upstream or within exons 7–18, which code for the helicase core of BLM. The most common
Bloom syndrome mutation is a 6 bp deletion/7 bp insertion in exon 9 (6‐BP DEL/7‐BP
INS, rs113993962:ATCTGA>TAGATTC) (Ellis et al. 1994, 1998; Li et al. 1998; Straughen
et al. 1998; German et al. 2007). This frameshift indel mutation changes the amino acids encoded
by codons 736–739 before causing a premature stop in codon 740 (p.Tyr736fsX4). This
mutation, also referred to as blmAsh, occurs with a frequency of ~0.01 in the Ashkenazi Jewish
population (Li et al. 1998). In addition to mutations causing premature chain termination, 13
missense mutations in the ATPase and RQC domains of the BLM helicase core have been
identified in persons with Bloom syndrome (Ellis et al. 1995; Foucault et al. 1997; Barakat
et al. 2000; German et al. 2007). Seven of the missense mutations alter amino acid residues in the
ATPase domain (Q672R, I841T, C878R, G891E, C901Y, G952V, H963Y) whereas the six
missense mutations in the RQC domain mostly affect the highly conserved cysteine residues
involved in Zn coordination (C1036F, C1055S, C1055R, C1055G, D1064V, C1066Y) (Fig. 1A).
The lack of differences in the expression of Bloom syndrome between individuals with these
missense mutations, either in the homozygous or compound heterozygous state, and individuals
with early chain‐terminating mutations suggests that they all inactivate BLM (Ellis et al. 1995).
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There is some evidence that heterozygosity for BLM mutations leads to increased
colorectal cancer risk in humans and mice (Goss et al. 2002; Gruber et al. 2002), and causes
increased sensitivity to DNA‐damaging agents in a diploid yeast model (Mirzaei and
Schmidt 2012). However, it is unclear if besides fully inactivating mutations that cause Bloom
syndrome other naturally occurring BLM mutations cause more subtle functional defects that
might be new cancer risk factors in otherwise healthy individuals. To address this question we
used a yeast model to screen coding single nucleotide polymorphisms (SNPs) in the human BLM
gene for those that impair BLM function as estimated by the hypersensitivity of cells to HU
(Mirzaei and Schmidt 2012). This yeast model expressed a chimera of the N‐terminal 648
residues of Sgs1 (the BLM‐related RecQ helicase in Saccharomyces cerevisiae) and the C‐
terminal 800 residues of human BLM to which 41 nonsynonymous SNPs from the Short Genetic
Variations database (dbSNP) map. We ranked these 41 coding SNPs and two additional SNPs
reported in the literature (German et al. 2007) based on their probability to impair BLM function
using PolyPhen (Ramensky et al. 2002) and evaluated the 22 SNPs predicted to be ‘probably’ or
‘possibly’ damaging (PolyPhen score >1.5) for their effect on BLM function in vivo (Mirzaei
and Schmidt 2012). The screen identified eight SNPs that impaired BLM function, all of which
had a PolyPhen score >2 (rs761589072:C>T, P690L; rs28406486:G>C,
R717T; rs55880859:C>T, R791C; rs148394770:T>C, W803R; rs145029382:A>G,
Y811C; rs2227935:C>T, P868L; rs150475674, G972V:G>T; rs139773499:G>A, G1120R)
(Table 1) (Fig. 1A). Interestingly, this screen suggested that in addition to rare null alleles that
had not yet been associated with Bloom syndrome more common BLM alleles may also be
functionally impaired. The higher frequency of these alleles in the human population
(e.g. rs2227935:C>T, P868L; 5.13%) suggests that they are insufficient for full‐scale Bloom
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syndrome, but their lower functional activity may lead to an increased cancer risk later in life or
an increased risk for developing other symptoms of Bloom syndrome, such as type 2 diabetes
mellitus or fertility problems. Here, we have quantified functional defects of cells expressing
these new BLM alleles, with an emphasis on the first three hypomorphic BLM allele candidates
(rs2227935, rs55880859, rs139773499) by assessing chromosomal abnormalities, their ability to
respond to genotoxic agents and their ability to repair DSBs.
MATERIALS AND METHODS
Cell lines, plasmids, and transfection
GM08505 is an SV40‐transformed skin fibroblast cell line established from a patient with
Bloom syndrome (Ellis et al. 1995) and was obtained from Coriell Cell Repository. GM00637 is
an SV40‐transformed skin fibroblast cells line from an unaffected individual (Coriell Cell
Repository). Cells were grown in minimal essential medium (Corning, Tewksbury, MA)
supplemented with 10% FBS and 2 mmol/L glutamine at 37°C in the presence of 5% CO2.
GM08505 cells were plated 24 h before transfections at approximately 2 × 104 per cm2. BLM
cDNA cloned into pcDNA3 vector and mutated at stated sites using site‐directed mutagenesis
was transfected using Polyfect (Qiagen, Valencia, CA). Stable clones were selected in the
presence of G418 (750 μg/mL). Clones were maintained in the presence of G418 (350 μg/mL).
BLM cDNA in pcDNA3 was a kind gift from Dr. Ian Hickson, University of Copenhagen. Cell
lines expressing the BLM variants evaluated in this study are listed in Table 2.
Subcellular fractionation and western blotting
Nuclear extracts were prepared from exponentially growing cells to detect BLM
expression. Cells were lysed in 20 mmol/L Tris pH 7.4, 10 mmol/L KCl, 1 μmol/L EDTA, 0.2%
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NP40, 50% glycerol, 0.6 mmol/L β‐mercaptoethanol, 1 mmol/L PMSF, and protease inhibitor
cocktail (Pierce, Rockford, IL), followed by nuclear extraction in 20 mmol/L Tris pH 7.4, 10
mmol/L KCl, 0.4 mol/L NaCl, 1 mmol/L EDTA, 50% glycerol, 0.6 mmol/L BME, 1 mmol/L
PMSF, and protease inhibitor cocktail (Pierce). Mouse monoclonal antibody BLM‐F5 (SCBT,
Dallas, TX) was used to detect BLM and a monoclonal tubulin antibody (Abcam, Cambridge,
MA) was used as a loading control.
Differential sister‐chromatid staining
Sister chromatid exchanges (SCEs) were quantified using protocols described previously
(Perry and Wolff 1974; Bayani and Squire 2001; Campos et al. 2009). Briefly, cells were
cultured for two cell cycles in growth medium supplemented with BrdU Labeling Reagent (Life
Technologies, Carlsbad, CA) and metaphase arrest was induced by the addition of 0.1 μg/mL
colcemid for 1 h. Chromosome spreads were prepared after hypotonic treatment with 75 mmol/L
KCl and fixation with 3:1 (vol/vol) methanol‐acetic acid. Metaphase spreads were differentially
stained using Hoechst 33258 (75 μg/mL; Life Technologies) and Giemsa (3.5%; Life
Technologies). Images of intact metaphases were acquired on a Zeiss Axiovert 100
deconvolution microscope with a Plan‐Apochromat 100x/1.40 Oil DIC M27 objective Zeiss,
Thornwood, NY. For each cell line, a minimum of 1500 chromosomes were analyzed. The
mean ± SD is reported.
Clonogenic survival assay
Cells were seeded at a density of 500 cells/well for colony formation. On the next day,
either fresh medium containing HU (0.1, 0.2, 0.3, 0.4, or 0.5 mmol/L) or drug‐free medium was
added. The medium was removed after 48 h and cells were washed with PBS before colonies
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were allowed to grow in fresh complete growth medium for up to 4 weeks. Colonies were fixed
in 3:1 (vol/vol) methanol‐acetic acid and stained with 0.01% crystal violet. Colonies with more
than 50 cells were scored as survivors.
γH2AX accumulation and elimination
Exponentially growing cells were exposed to 1 μmol/L CPT for 1 h, released into fresh
media, and harvested at various time points (10 min, 20 min, 30 min, 45 min, 1 h, 8 h, 24 h, and
48 h). To detect γH2AX, chromatin fractions were prepared from nuclear extracts using
0.5 mol/L HCl, 50% glycerol, 100 mmol/L β‐mercaptoethanol and then neutralized using NaOH
in 40 mmol/L Tris pH 7.4 with protease inhibitor cocktail (Pierce) (Rios‐Doria et al. 2009).
Chromatin fractions were separated on 16% Tricine‐SDS polyacrylamide (Schagger 2006) and
Western blots were probed with PhosphoDetect Anti‐H2AX [pSer139] (Upstate Cell Signalling,
Billerica, MA) and polyclonal histone H3 antibody (Abcam). Changes in γH2AX levels with
respect to histone H3 levels were quantified using ImageJ (Rasband 1997). To inhibit PP2A‐
mediated dephosphorylation of γH2AX, 25 nmol/L okadaic acid was added to cells immediately
after CPT treatment.
Comet assay
Neutral comet assays were performed according to protocols described earlier (Olive and
Banath 2006; Nowsheen et al. 2012). Briefly, replication‐dependent DNA breaks were induced
by addition of 1 μmol/L CPT to cell cultures for 1 h. Cells were harvested immediately after
treatment and after growth in drug‐free media for 1, 24, and 48 h. Single cell suspensions in 1%
low melt agarose were plated on slides, lysed using neutral lysis buffer and electrophoresed for
30 min. Slides were fixed in 70% ethanol and stained with SYBR Gold (Life Technologies).
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Images were acquired on an UltraVIEW VoX Life Cell Imager (Perkin Elmer, Waltham, MA)
equipped with a Zeiss Axiovert 200 and a 20x/0.8 M27 Plan‐Apochromat objective using
Volocity software. At least 50 comets were imaged for three independent cell lines for a
minimum of 150 comets at each time point. The mean of the tail DNA percentage was calculated
using OpenComet (Gyori et al. 2014).
RESULTS
Skin fibroblast cell lines established from persons with Bloom syndrome (e.g.,
GM08505) exhibit a spontaneous, approximately 10‐fold increase in the frequency of SCEs
compared to cells from unaffected persons; they also present with quadriradial chromosomes in
metaphase spreads, are hypersensitive to HU, and show a delay in activating the DNA damage
response after exposure to the topoisomerase poison CPT. To determine the ability of eight SNPs
that cause single amino acid changes in BLM (Table 1) to complement the cellular defects of
Bloom syndrome cells, the SNPs were introduced into BLM cDNA in vector pcDNA3 and
expressed in cell line GM08505, in which both BLM alleles are inactivated by
the blmAsh mutation. For each of the eight BLM variants at least three stable cell lines, expressing
each BLM variant at levels similar to that of wildtype BLM in a skin fibroblast cell line from an
unaffected individual (GM00637), were constructed and analyzed for DNA‐damage sensitivity
using a clonogenic (survival) assay (Fig. 1). Expression of wildtype BLM improved survival of
Bloom syndrome cells GM08505 in the presence of HU to that of GM00637, whereas expression
of P690L, R717T, W803R, Y811C, and G972V caused no improvement (Fig. 1C), suggesting
that they eliminate BLM function. Survival of GM08505 cells expressing the R791C, P868L and
G1120R variants, however, was not significantly different from wildtype BLM (Fig. 1D).
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The decreased ability of BLM‐deficient cells to dissolve intermediates of HR as
noncrossovers is thought to be a cause of the increased frequency of exchange of genetic
material between sister chromatids, which can be visualized by differential staining with
Hoechst/Giemsa after two rounds of cell division in the presence of the thymidine analog BrdU
(Perry and Wolff 1974) (Fig. 2B, panel a). We measured a 12‐fold increase in the SCE frequency
in GM08505 cells compared to GM00637 (Fig. 2A), consistent with previous findings in cell
lines derived from persons with Bloom syndrome (Ellis et al. 1999). Since the P690L, R717T,
W803R, Y811C, and G972V mutations caused the same HU hypersensitivity in human cells as
the known Bloom syndrome causing blmAsh mutation (Fig. 1C), and the same HU
hypersensitivity as the helicase‐dead blm‐K695A mutation in yeast (Mirzaei and Schmidt 2012)
we focused the evaluation of chromosome abnormalities on the R791C, P868L, and G1120R
alleles, and only included two representatives from the group of null alleles, P690L (Walker A
motif) and W803R (conserved aromatic‐rich loop). As expected, we found that expression of
wildtype BLM in GM08505 lowered the SCE frequency to levels seen in normal fibroblasts
whereas expression of variants that exhibited a null phenotype in the HU survival assay had no
significant effect on SCE frequency, remaining 7‐fold (P690L) to 8‐fold (W803R) higher than
cells expressing wildtype BLM (Fig. 2A). Expression of variants R791C, P868L, and G1120R,
which suppressed HU hypersensitivity of GM08505 cells as effectively as wildtype BLM,
lowered SCE frequency of Bloom syndrome cells (P < 0.01) (Fig. 2A), but levels were still
significantly higher (4–5‐fold, P < 0.01) than in cells expressing wildtype BLM, indicating
reduced BLM activity.
In contrast with genetic exchange between sister chromatids, recombination between
homologous chromosomes can give rise to LOH; it can thus be considered mutagenic and a
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driver of tumorigenicity in Bloom syndrome. Such recombination events between nonsister
chromatids of homologous chromosomes and, potentially, nonhomologous chromosomes are
captured in metaphase spreads as quadriradial chromosomes (Fig. 2B, panel d). As expected, we
did not find quadriradials in normal GM00637 fibroblasts, but observed ~13 for every 10
metaphases in GM08505 cells (Fig. 2C). Quadriradial formation was reduced ~5‐fold to fewer
than three quadriradials for every 10 metaphases upon expression of wildtype BLM. The same
reduction was achieved by expression of R791C, P868L, and G1120R, whereas quadriradials
still formed readily in GM08505 cells expressing P690L or W803R (Fig. 2C).
In addition to increased recombination events between sister and nonsister chromatids,
cells from Bloom syndrome patients show a delay in the induction of the DNA damage response
after exposure to genotoxic agents, such as CPT (Rao et al. 2005), which at low concentrations
(≤1 μmol/L) induces replication‐specific DSBs (Holm et al. 1989; Pommier 2006).
Phosphorylation of the histone H2A variant H2AX at serine 139 is one of the first markers of
DSB formation in eukaryotic cells (Rogakou et al. 1998). Phosphorylated H2AX, γH2AX, is
thought to recruit and retain DNA damage response and repair factors at DSBs and increase their
accessibility to the DSB site by facilitating chromatin remodeling (Celeste et al. 2002;
Fernandez‐Capetillo et al. 2002; Stucki et al. 2005; Tsukuda et al. 2005; Kolas et al. 2007).
Results obtained from an H2AX‐S139A mutant suggest that H2AX phosphorylation also plays a
role in checkpoint activation (Rios‐Doria et al. 2009). Upon completion of DSB repair,
elimination of γH2AX, either by dephosphorylation or exchange with H2AX, is needed for cell
cycle progression (Rogakou et al. 1998; Chowdhury et al. 2005; Keogh et al. 2006). To
determine the effect of BLM variants on the induction of the DNA damage response we exposed
cells to 1 μmol/L CPT for 1 h, removed the drug, and assessed the accumulation of γH2AX every
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10 min for 1 h (Fig. 3). To follow completion of DSB repair and cessation of the DNA damage
response we extended this time course to 48 h to evaluate the kinetics of the elimination of
cellular γH2AX. γH2AX accumulation in Bloom syndrome cells complemented with wildtype
BLM peaked 1 h after CPT removal and then γH2AX levels declined rapidly, being undetectable
by Western blot after 24 h (Fig. 3A, Fig. S1). In contrast, in Bloom syndrome cells γH2AX levels
did not peak until 32 h after drug removal and declined only slowly, with most of the H2AX still
phosphorylated after 48 h (Fig. 3B). Bloom syndrome cells expressing the P690L variant, a
representative of the five alleles that were hypersensitive to HU in human cells and in yeast,
followed the same kinetics of γH2AX accumulation and elimination as Bloom syndrome cells,
further supporting the null phenotype of this BLM variant (Fig. 3C). Interestingly, in Bloom
syndrome cells expressing R791C, P868L, or G1120R mutations, γH2AX accumulation reached
its peak 1 h after CPT removal as in cells expressing wildtype BLM, but there was distinctly
less γH2AX, especially at early time points. Even more noticeable, at the 24‐hour time point,
when γH2AX was undetectable in complemented Bloom syndrome cells, most of the γH2AX
was still present in these mutants, thus resembling the severely delayed elimination of γH2AX in
Bloom syndrome cells (Fig. 3D–F, Fig. S1).
We therefore wanted to test if this impaired elimination of γH2AX in cells with the
intermediate phenotype (Fig. 3D–F) affected the cells' ability to mount a response to repeated
exposure to a genotoxin. We first tested Bloom syndrome cells complemented with wildtype
BLM. Cells were exposed to 1 μmol/L CPT for 1 h and then released into media without CPT,
with aliquots being removed every 10 min for 1 h and again after 8 h since at this time
point γH2AX levels had declined significantly (Fig. 3A). At this 8 h time point cells were again
exposed to 1 μmol/L CPT for 1 h, released into fresh media, and aliquots collected at the same
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time points as in the first cycle (Fig. 4A). The kinetics of the two cycles of H2AX
accumulation/elimination were nearly indistinguishable, suggesting that wildtype cells were
capable of mounting proficient responses to repeated insults from CPT. To test blm‐P868L, the
intermediate BLM variant with the highest allele frequency in the human population (5.13%), we
exposed cells to a second dose of CPT after 24 h (instead of 8 h) because only then did we start
to see significant elimination of γH2AX (Fig. 3E). As wildtype cells, blm‐P868L cells responded
equally well to both exposures of CPT; however, with a marked >16 h delay in γH2AX
elimination in both cycles (Fig. 4B). Despite lower initial H2AX phosphorylation and severely
delayed dephosphorylation compared to wildtype cells, blm‐P868L cells responded significantly
better to repeated CPT exposure than Bloom syndrome cells (Fig. 3 and 4C).
At low concentrations (<50 nmol/L) okadaic acid selectively inhibits the γH2AX
phosphatase PP2A (Honkanen and Golden 2002). Loss of PP2A activity has been shown to
cause cell cycle changes, increased sensitivity to DNA damaging agents, and delay in DNA
repair, probably enhanced by affecting the activity of other PP2A substrates in addition H2AX,
such as ATM, Chk2, and DNA‐PK (Douglas et al. 2001; Dozier et al. 2004; Goodarzi
et al. 2004; Chowdhury et al. 2005). Bloom syndrome cells complemented with BLM or blm‐
P868L survived treatment with 25 nmol/L okadaic acid with sustained maximum levels
of γH2AX (Fig. S2), whereas Bloom syndrome cells died. To test if the marked delay in γH2AX
accumulation and elimination after CPT removal in cells expressing P868L corresponded to
unrepaired DSBs, we performed a neutral comet assay (Fig. 5). Cells were exposed to 1 μmol/L
CPT for 1 h and released into fresh media, with cells being removed for lysis and electrophoresis
at the end of the incubation with CPT (0 h) and then after 1, 24, and 48 h. In wildtype cells, DNA
breaks were significantly reduced over the 48 h time course, with 23% and 14% of DNA damage
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remaining after 24 and 48 h respectively. In blm‐P868L cells twice as much DNA damage
(28%, P < 0.0001) was still unrepaired after 48 h, indicating a lag of DNA repair of at least 24 h.
This presents a significant loss in DNA break repair activity of the P868L variant, but not as
great as that of Bloom syndrome cells where the amount of unrepaired DNA breaks after 48 h
was three times higher (43%, P < 0.0001) than in wildtype cells.
DISCUSSION
In this study, we have identified variable functional defects of novel variants of the
tumor‐suppressor BLM. Five of the eight variants cause cellular defects that are
indistinguishable from those of Bloom syndrome cells, indicating that they encode nonfunctional
BLM variants that would cause Bloom syndrome in the homozygous or compound heterozygous
state. The amino acid changes in these five BLM variants – P690L, R717T, Y811C, W803R,
G972V – cluster along the catalytic cleft between the N‐terminal and the C‐terminal lobe of the
ATPase domain of the helicase core. Residues that make up the seven conserved helicase motifs
of BLM are located at the surface of this cleft to bind ATP, Mg2+ and single‐stranded DNA and,
eventually, to hydrolyze ATP. The null phenotype exhibited by the five BLM variants can be
explained by the location of the mutated residues in or near these conserved helicase motifs.
These new null alleles are the first to inactivate BLM by mutation of residues in or near motifs I
(P690L), Ia (R717T), VI (G972V), and the conserved aromatic loop (W803R, Y811C), whereas
the known Bloom syndrome‐associated amino acid changes map to motifs 0 (Q672R) and IV
(G891E, C901Y) or fall outside of the conserved motifs (I841T, C878R) (Guo et al. 2007). The
location of the new missense mutations in the (Walker A) motif I for ATP binding or in other
conserved helicase motifs suggests that the null phenotype of the new BLM variants is due to
loss of ATPase activity. While it is not surprising that ATPase activity would be required for
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BLM's role in suppressing SCEs by dissolving dHJ as noncrossovers, our findings also implicate
ATPase activity in the role of BLM as a transducer of H2AX phosphorylation in response to
replication‐dependent DSBs (Rao et al. 2005), most likely to mediate early events (e.g.,
resection, unwinding) at collapsed replication forks. Resembling the known Bloom syndrome
causing missense mutations, with each having been identified in only one person (German
et al. 2007), the new null variants are very rare in the human population, with allele frequencies
of <0.01 (Sherry et al. 2001, Exome Variant Server, 2015).
In addition to new null alleles, we identified the first BLM variant, P868L (rs11852361),
that exhibits some, but not all, defects of Bloom syndrome causing mutations and does not, based
on its relatively high allele frequency, cause Bloom syndrome. The frequency of P868L in the
human population is 5.13%, ranging from 0.6% in the Japanese to 12.3–15.3% (15/122 alleles,
1000 Genomes Project Consortium; 15/98 alleles, CSHL‐HAPMAP) in the population of African
descent in the South Western United States (ASW) (International HapMap, 2003, Thorisson
et al. 2005, 1000 Genomes Project Consortium, 2012). Homozygosity for P868L in the ASW
population was 1 in 61 (1/61 genomes, 1000GENOMES) and 1 in 25 (2/49 genomes, CSHL‐
HAPMAP), with the next highest frequencies in the Finnish (3/93 genomes) and the British (2/89
genomes) (International HapMap Consortium 2003, Thorisson et al. 2005, 1000 Genomes
Project Consortium 2012). In our study, cells expressing the P868L variant exhibited a
significantly elevated SCE frequency (Fig. 2A), an aberrant (slow) DNA‐damage response, and
inefficient repair of DNA‐damage‐induced, replication‐dependent DSBs (Fig. 3B). On the other
hand, blm‐P868L expressing cells showed similar HU sensitivity and frequency of quadriradial
chromosomes as cells expressing wildtype BLM. When mapped onto the recently released
crystal structure of human BLM (Swan et al. 2014), P868L affects a residue in a loop of
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unknown function in the C‐terminal lobe of the ATPase domain. This lysine‐rich loop is not near
the catalytic cleft where the null mutations map, but instead appears to contact double‐stranded
(ds) DNA bound by the WH domain just before it is unwound (Fig. 6A). Based on this location
we propose that replacing the helix breaker proline with hydrophobic leucine disrupts the
flexibility and hydrophilicity of the loop, weakening dsDNA binding. Biochemical analysis of
the purified BLM variant will be necessary to determine if less efficient dsDNA binding, in and
of itself, causes the slower and abnormal DNA break repair exhibited by the P868L variant, or if
it is due to less efficient ATP hydrolysis since the ATPase activity of BLM is single‐stranded (ss)
DNA‐dependent.
In addition to P868L we identified two other BLM variants that fall into this new class of
intermediate (hypomorphic) mutations. G1120R is the first BLM missense mutation from the
human population that maps to the WH domain and impairs BLM function. The WH domain is
conserved structurally, but not at the amino acid level. We found that one of the few exceptions
is the first glycine (G1120) in the loop between the second and third α‐helix of the domain (α2–
α3 loop), which is conserved in members of the RecQ helicase family from bacteria, to yeast, to
humans. It is still unclear how the WH domain contributes to BLM function since BLM lacking
this domain still possesses helicase activity (Gyimesi et al. 2012). Nonetheless, the loop with
G1120 has been shown to expand in the related human RecQ helicase WRN upon DNA binding,
exposing an arginine for dsDNA binding (Kitano et al. 2010). Similarly, the corresponding loop
in the recently released crystal structure of human BLM is near dsDNA (Swan et al. 2014)
(Fig. 6 B). We propose that the G1120R mutation, by removing the helix‐terminating glycine,
extends the α2‐helix, eliminating or at least reducing the loop structure for dsDNA binding.
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Unlike P868L, G1120R is rare, having been identified once in 2197 genomes (Exome Variant
Server 2015).
The third hypomorphic BLM variant that causes elevated SCEs and inefficient DNA
break repair, but normal HU sensitivity and wildtype frequency of quadriradial chromosomes, is
R791C. The affected residue is in the N‐terminal lobe of the ATPase domain in the internal β‐
sheet that precedes helicase motif II (Walker B) required for Mg2+ binding and ATP hydrolysis
(Fig. 6C). Hence, the DNA break repair defect of cells expressing the R791C variant is likely
due to diminished ATPase activity. The allele has been identified once in 97 genomes from the
Han Chinese in Beijing (1000 Genomes Project Consortium 2012) and twice in 6496 genomes
from European‐American and African‐American populations in the United States (Exome
Variant Server 2015). Although R791C is so rare it is listed three times in The Cancer Genome
Atlas (TCGA); twice in nonsmall cell lung carcinoma and once in a lymphoid neoplasm
(Barretina et al. 2012), raising the possibility that it contributes to tumorigenesis.
Taken together, we have identified five new BLM missense mutations that exhibit defects
of the Bloom syndrome associated blmASH null allele and are therefore new candidates for Bloom
syndrome causing alleles, and three new BLM missense mutations that exhibit some defects
(elevated interchromatid crossover recombination (SCEs), slower accumulation and markedly
delayed elimination of γH2AX after genotoxin exposure, and inefficient repair of replication‐
dependent DSBs), but not others (HU hypersensitivity, accumulation of quadriradial
chromosomes) (Table 2). H2AX and its phosphorylation at S139 have been shown to play a role
in DSBR by HR between sister chromatids, which is potentially error‐free (Kadyk and
Hartwell 1992; Johnson and Jasin 2000), while preventing error‐prone HR, such as single‐strand
annealing (SSA) (Xie et al. 2004). Thus, the severe delay in γH2AX accumulation in cells
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expressing BLM null alleles (e.g. P690L, R717T, W803R, Y811C, and G972V in this study),
and the lesser, but significant, delay in cells expressing the P868L, G1120R, or R791C variants
may be indicative of dysregulation of DSBR, resulting in increased utilization of SSA or HR
between homologs, which are prone to deletions and LOH respectively. In contrast with H2AX
phosphorylation and its effects on DSBR, the signaling of γH2AX elimination and the
consequences of persistence of γH2AX, as seen in cells expressing fully or partially defective
BLM variants in this study, are less well‐understood, but involves direct dephosphorylation by
PP2A‐B56ε (Xie et al. 2004; Chowdhury et al. 2005). Our findings indicate that the requirement
of BLM for the accumulation of γH2AX (Rao et al. 2005) extends to its enzymatic activity,
suggesting its requirement for DNA processing rather than protein binding or recruitment at
DSBs. Our findings further extend the role of BLM's enzymatic activity to the elimination
of γH2AX. Our assays cannot distinguish whether BLM is part of the signaling pathway
for γH2AX elimination or the effect is solely through BLM's role in DSB processing and
rejoining, but the severely delayed (>40 h) elimination of cellular γH2AX is associated with
delayed and, possibly, error‐prone DNA damage repair as well as delays in restoration of
chromatin integrity and the cell cycle.
The functional evaluation of new BLM variants in this study also provides insight into
the in silico predictability of the impact of SNPs on BLM function (Table 1). Initially we used
Polyphen (Ramensky et al. 2002) to rank 43 coding SNPs in BLM, with 22 scoring as either
probably or possibly damaging. All eight SNPs that are functionally impaired in yeast and in
human cells were predicted to be ‘probably damaging’ (score > 2). However, Polyphen was
unable to distinguish between the null alleles and the intermediate/hypomorphic alleles. Its
successor, PolyPhen2 (Adzhubei et al. 2010), had enhanced predictability, classifying P868L as
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an intermediate (possibly damaging) allele. In contrast, both SIFT (Kumar et al. 2009) and FIS
(Reva et al. 2011) categorized R717T as being ‘tolerated’ or of ‘low’ impact respectively. Thus,
for our limited set of variants, this comparison suggests that for the evolutionarily conserved and
highly structured catalytic core of BLM, Polyphen2 was the most accurate predictor of functional
impact.
The biological relevance of the functional defects of the new class of intermediate BLM
variants for human health and aging is currently unclear, as is their importance for a person's
sensitivity to genotoxins. Although all defects caused by hypomorphic BLM variants were
significantly less pronounced than in Bloom syndrome cells, any increased mutation load over a
person's lifetime is likely to be associated with increased cancer risk; this risk is known to be
extraordinarily high for BLM null alleles, leading to Bloom syndrome, and now remains to be
defined for the newly identified class of hypomorphic BLM variants, currently represented by
R791C, P868L, and G1120R.
FUTURE DIRECTIONS
SNPs have also been reported in the region coding for the BLM N-terminal tail (Sherry et
al. 2001). Whereas the C-terminal region of BLM exhibits a high degree of sequence and
structure conservation, the N-terminal region is predicted to be highly disordered with very little
sequence similarity between its orthologs. The N-terminal region constitutes a long (~639
residues) tail and like the N-terminus of other RecQ helicases is biologically functional as the
binding site for protein interactions. However, the mutational approach used to characterize and
understand the C-terminal region BLM and other RecQs cannot be used for the intrinsically
disordered BLM-terminal region. Given its role in complex with other proteins to preserve
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genomic stability (Hickson 2003; Bachrati et al. 2006; Daley et al. 2014; Sturzenegger et al.
2014, Croteau et al. 2014), identifying single residue alterations disrupting BLM interactions
with specific binding partners while not impacting others would be a good approach to delineate
the functions of BLM in different pathways.
Based on PolyPhen2 predictions of impaired function and the predicted presence of αhelical regions indicating protein binding propensity (Adzhubei et al. 2010; Muñoz & Serrano
1994; Dyson &Wright 2002), the following 16 SNPs have been identified as candidates for
functional evaluation — A2S, V4A, R15C, L60I, D64V, K17R, E140G, F160S, D239H, S269G,
D295Y, K323R, A363T, L401F, L410F, E507K (Table S2.1). Single residue changes within an
α-helix have been shown to disrupt Sgs1/Top3 interaction (Kennedy et. 2013). The
corresponding Topo IIIα interacting region in BLM contains a helical region, which is predicted
to be disrupted by R15C (Figure S2.3). Furthermore, S269G is predicted to disrupt an α-helix in
the region involved in BLM/p53 binding (Figure S2.3). K137R and E140G also map to regions
with increased helical content, but are not predicted to be as disruptive. However, they are
located in the region involved in BLM dimerization as well as interacting with Topo IIIα and
Rad51 (Wu et al. 2000; Bergeron et al. 2012).
As a preliminary step towards this approach, we tested the ability of a few BLM Nterminal variants to suppress HU sensitivity and complement defective response to CPTmediated replication stress in GM08505 cells. Similar to the three hypomorphic variants
identified in the BLM C-terminal region, all BLM N-terminal variants tested were able to
suppress HU sensitivity as well as wildtype BLM (Figure S2.4). On the other hand, the response
to CPT-mediated replication stress was varied. While γH2AX accumulation appeared to be
similar to wildtype BLM, every BLM N-terminal variant except D64V exhibited varying degrees
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of delay in γH2AX elimination. Cells expressing the S269G, F160S and E140G variants showed
a more pronounced delay in the γH2AX elimination profile (Figure S2.5). Based on this, we
selected S269G to perform a neutral comet assay along with the hypomorphic variant P868L.
Based on the role of the BLM/Topo III α /RMI1/2 complex in DSBR, we assayed the R15C
variant as well. Remarkably, both R15C and S269G exhibit a loss of DSBR efficiency similar to
P868L.
The preliminary data suggests that single residue changes within putative structural
elements in the BLM N-terminal tail can be functionally characterized using assays utilized to
evaluate C-terminal variants. This opens up the possibility of identifying separation of function
alleles. Further, rationally designed mutations disrupting these predicted regions can be of use to
understand the underlying mechanism of functional defects of population derived SNPs.
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FIGURES AND TABLES

Figure 2.2. Ability of BLM variants to complement the hydroxyurea sensitivity of the
BLM‐deficient cell line GM08505.
(A) Map of human BLM with conserved helicase motifs I‐VI, the RecQ‐C‐terminal (RQC)
domain consisting of Zn‐binding and winged helix (WH) subdomains, and the Helicase‐ and
RNaseD‐C‐terminal (HRDC) domain. Sites of known Bloom syndrome causing missense
mutations are indicated above the map and locations of BLM variants analyzed in this study are
indicated below the map. (B) GM08505 cells, which are homozygous for the blmASH mutation
and do not express full‐length BLM (lane 2), express stably transfected BLM variants (lanes 4–
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11) at similar levels as wildtype BLM (lane 3). Endogenous BLM expression in the normal
fibroblast cell line GM00637 is shown lane 1. (C–D) Cells were exposed to increasing
concentrations of hydroxyurea (0.1–0.5 mmol/L) for 48 h and survivors (colonies with ~50 or
more cells) were counted after up to 4 weeks of growth in hydroxyurea‐free media. Three
independently generated stable cell lines were analyzed for BLM and every BLM variant.
Mean ± SD is shown.

Figure 3.2. Chromosomal aberrations in GM08505 cells expressing BLM variants
(A) Analysis of sister‐chromatid exchanges (SCEs) by differential sister‐chromatid staining of
metaphase chromosomes identifies two groups of BLM variants; variants that cause
hypersensitivity to HU (see Fig. C), here represented by P690L and W803R, show SCE levels
similar to GM08505, whereas variants that do not cause hypersensitivity to 0.5 mmol/L HU
(R791C, P868L, G1120R) (Fig. D) had reduced levels of SCEs compared to Bloom syndrome
cells, but levels were still higher than in GM08505 cells expressing wildtype BLM. SCEs per 46
metaphase chromosomes are shown. (B) Types of chromosomal aberrations commonly observed
in Bloom syndrome cells include (a) SCEs, (b) chromatid gaps, (c) segmented chromosomes, and
(d) quadriradial chromosomes. (C) Appearance of quadriradial chromosomes in metaphase
spreads of GM08505 cells expressing BLM variants R791C, P868L, and G1120R is reduced to
wildtype levels, whereas expression of P690L or W803R variants caused significantly elevated
formation of quadriradial chromosomes.
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Figure 2.3. Response of Bloom syndrome cells (GM08505) expressing BLM variants to
replication‐dependent DNA breaks
DNA breaks were induced by exposure to 1 μmol/L CPT for 1 h. Accumulation and elimination
γH2AX in comparison to histone H3 was quantified by Western blot of extracts from cells
collected over a 48 h time course (Fig. S1). Increasing levels of γH2AX are indicated in red, and
declining levels in blue. Three independent, stable cell lines were analyzed for GM08505 cells
expressing wildtype BLM (A) or BLM variants (C–F). Mean ± SD is shown.
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Figure 2.4. DNA‐damage response after repeated induction of DNA breaks by
camptothecin (CPT)
(A) GM08505 + BLM cells were exposed to 1 μmol/L CPT for 1 h, released into drug‐free
media, and γH2AX levels analyzed by Western blot every 10 min for 1 h and again after 8 h. At
the 8‐hour time point cells were exposed to a second round of 1 μmol/L CPT treatment since at
this point γH2AX levels in GM08505 + BLM cells had significantly declined (see Fig. A).
γH2AX levels were analyzed again every 10 min for 1 h and then after 8 h. (B) Cells expressing
variant P868L were exposed twice to CPT as in (A), but the second exposure to CPT occurred
after 24 h since this was the first time point at which a significant decline in γH2AX was
detected in cells expressing the P868L variant (see Fig. E). (C) Comparison of γH2AX
accumulation in the first hour after CPT removal. γH2AX levels were quantified by Western blot
for GM08505 cells and three independent stable cell lines expressing wildtype BLM or the
P868L variant. Western blots were analyzed using ImageJ (Schneider et al. ). Mean ± SD is
shown.
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Figure 2.5. Efficiency of repair of replication‐dependent DNA double‐strand breaks
(A) Neutral comet assay indicates varying levels of double‐strand break repair 24 h after CPT
treatment of GM08505 cells expressing no BLM, wildtype BLM, or BLM variant P868L. (B)
Tail DNA content was quantified with OpenComet in 150 comets from GM08505 cells and three
independent stable cell lines expressing BLM or BLM variant P868L. Mean ± SD is shown. The
asterisks indicates P < 0.001.
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Figure 2.6. Location in the crystal structure of human BLM of amino acid changes with
intermediate functional impact
(A) P868L maps to a lysine‐rich loop at the periphery of the C‐terminal lobe of the ATPase
domain. The loop appears to be in contact with dsDNA, which is also contacted by the WH
domain. P868L is at the C‐terminal end of a β‐strand that transverses lobe 2 of the ATPase
domain from the catalytic cleft to the periphery where DNA is contacted, possibly connecting
DNA‐substrate binding to ATP‐hydrolysis. The crystal structure of BLM in a complex with ADP
and duplex DNA is from PDB (ID: 4O3M). (B) G1120 is located in a loop between the second
and third α‐helix of the WH‐domain that contacts dsDNA. BLM crystal structure is PDB ID
4O3M. (C) R791 maps to an internal β‐strand that precedes the loop of the Walker B motif
involved in Mg2+‐binding and ATP hydrolysis. Since the loop in helicase motif II (Walker B) is
not resolved in 4O3M (Swan et al. ), the R791C mutation is shown in BLM crystal structure
4CDG (Newman et al. ). The amino acid residues changed by the missense mutations are shown
as red spheres. Images were generated with PyMOL v1.3.
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Figure S2.1. Response GM08505 expressing BLM variants to replication‐
dependent DNA breaks
Representative examples of the response of Bloom syndrome cells (GM08505)
expressing wildtype BLM and BLM variants to replication-dependent DNA breaks
induced by exposure to 1 μM CPT for 1 hour. Accumulation and elimination of
γH2AX was determined by Western blot over a 48-hour time-course.

Figure S2.2. Effect of PP2A inhibition on γH2AX accumulation in Bloom syndrome cells
expressing wildtype BLM and hypomorphic BLM variants
Cells were exposed to 1 μM CPT for 1 hour and released into media with 25 nM ocadaic acid
(OA). H2AX phosphorylation levels were determined after 0.5, 8 and 24 hours. Noncomplemented Bloom syndrome cells were not viable at the 24 hour time point.
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Figure S.2.3. Disruption of predicted helical content in BLM N-terminal region
R15C and S269G disrupt predicted α-helical content in the Topo III α and p53 binding regions
respectively.
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Figure S2.4. Ability of BLM N-terminal variants to suppress HU sensitivity of GM08505
cells
GM08505 cells expressing various BLM variants were exposed to increasing HU concentrations
and surviving colonies were scored after four weeks. Three independently generated stable cell
lines were analyzed for BLM and every BLM variant. Mean +/-SD is shown.
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Figure S2.5. Response of cells expressing BLM N-terminal variants to CPT mediated DNA
double strand break
Accumulation and elimination γH2AX was quantified with respect to histone H3 levels by
Western blot. Increasing levels of γH2AX are indicated in red, and declining levels in blue.
Three independent, stable cell lines were analyzed for GM08505 cells expressing wildtype BLM
or BLM variants. Mean ± SD is shown.
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Figure S2.6. Replication dependent DNA double-strand break repair efficiency of cells
expressing BLM N-terminal variants
Tail DNA% from 150 neutral comets from GM08505 cells and three independent stable cell
lines expressing wildtype BLM or BLM variants was quantified using OpenComet. Mean ± SD
is shown.
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Table 2.1. Overview of BLM variants evaluated in this study
Prediction Tools
Nucleotide changea

Amino acid changeb

Allele Frequency

PolyPhenc

PolyPhen2d

SIFTe

FISf

Cell line ID

c.2069C>Tg

p.Pro690Leu

n.a.

■ 2.724

■1

■0

■ 4.875

KSVS1405

c.2150G>C

p.Arg717Thr

rs28406486

n.a.

■ 2.008

■ 0.985

■ 0.15

■ 0.85

KSVS1406

c.2371C>T

p.Arg791Cys

rs55880859

0.0002h

■ 2.495

■ 0.981

■ 0.01

■ 2.81

KSVS1402

c.2407T>C

p.Trp803Arg

rs148394770

n.a.

■ 3.757

■1

■0

■ 4.965

KSVS1407

c.2432A>G

p.Tyr811Cys

rs145029382

n.a.

■ 2.616

■1

■0

■ 4.955

KSVS1408

c.2603C>T

p.Pro868Leu

rs2227935

0.0513h

■ 2.724

■ 0.729

■ 0.02

■ 2.395

KSVS1403

c.2915G>T

p.Gly972Val

rs367543034

n.a.

■ 2.397

■1

■0

■ 2.295

KSVS1409

c.3358G>A

p.Gly1120Arg

rs139773499

n.a.

■ 2.172

■ 0.999

■0

■ 3.285

KSVS1404

dbSNP ID

blmAsh indel

0.01i

GM08505

WT

KSVS1415

a

GenBank RefSeq: NM _000057.3

b

GenBank RefSeq: NP_000048.1

c

Prediction using PolyPhen (http://genetics.bwh.harvard.edu/pph/index.html): red, probably damaging

d

Prediction using PolyPhen-2 (http://genetics.bwh.harvard.edu/pph/): red, probably damaging; yellow, possibly

damaging
e

Prediction using SIFT (http://sift.jcvi.org/): red, damaging; green, tolerated

f

Predicted Functional Impact Score via Mutation Assessor (http://mutationassessor.org/) ; red, high; yellow,

medium; low: green
g

From reference German et al. (2007)

h

Minor allele frequency from dbSNP (http://www.ncbi.nlm.nih.gov/SNP/)

i

Frequency in the Ashkenazi Jewish population from Li et al. (1998)
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Table 2.2. Summary of functional assays

Amino acid

HU

changea

sensitivityb

Chromosome abnormalitiesc
SCEs

Quadriradials

γ-H2AX

γ-H2AX

% DNA in

accumulationd

eliminationd

Comet Taile

p.Pro690Leu

+++

1.353±0.074

0.91±0.13

+++

+++

n.d.

p.Arg717Thr

+++

n.d.

n.d.

n.d.

n.d.

n.d.

p.Arg791Cys

+/-

0.774±0.044

0.190±0.09

+

++

n.d.

p.Trp803Arg

+++

1.506±0.238

0.696±012

n.d.

n.d.

n.d.

p.Tyr811Cys

+++

n.d.

n.d.

n.d.

n.d.

n.d.

p.Pro868Leu

+/-

0.809±0.116

0.130±0.07

+

++

63.16/19.14

p.Gly972Val

+++

n.d.

n.d.

n.d.

n.d.

n.d.

p.Gly1120Arg

+/-

0.941±0.102

0.182±0.08

+

++

n.d.

blmAsh indel

+++

1.44±0.05

1.330±0.16

+++

+++

70.40/32.40

-

0.18±0.05

0.272±0.12

-

-

67.84/10.22

WT

a

GenBank RefSeq: NP_000048.1

b

+++ significantly more sensitive to HU than wildtype cells at all tested HU concentrations (0.10.5 mM); +/- significantly more sensitive than wildtype cells at low HU concentrations (0.1-0.3
mM), but not significant difference at higher HU concentration (0.4-0.5 mM)
c

SCEs are shown as SCEs per chromosome with standard deviation; quadriradials are shown as
number of quadriradial chromosomes per metaphase with standard deviation; n.d. not determined
d

DNA damage response was assessed by accumulation and decline of phosphorylated H2AX; +
and +++ denote mild and severe delays in the accumulation and/or decline of phosphorylated
H2AX after treatment with 1 µM CPT; n.d. not determined
e

DNA double-strand breaks were visualized by means of neutral comet assay; % tail DNA 1 hr
post-release/% DNA 48 post-release after treatment with 1 µM CPT; n.d. not determined
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CHAPTER THREE:
GENERATION AND CHARACTERIZATION OF A DIPLOID BLM KNOCKOUT
CELL LINE
Note to reader: Unpublished data. Experiments were designed by Kristina H. Schmidt and Vivek
M. Shastri. All experiments were performed by Vivek Shastri.
INTRODUCTION
Bloom syndrome (BS) is a chromosomal instability disorder typified by highly elevated
SCE levels, increased chromosome breaks, and the presence of quadriradial chromosomes.
Furthermore, BS shows a strong correlation between chromosomal instability and an increased
predisposition to a wide range of cancers from a young age [1-3]. BLM directly functions in the
response to DNA damage and stalled replication forks [4-6]. Abnormal replication timing of both
early- and late-replicating loci in BS cells has been associated with constitutive DNA damage
[7]. BS cells have an increased frequency of ultrafine anaphase bridges, suggesting a role for
BLM in suppressing their formation and faithful chromosome segregation [8, 9]. Moreover, it
has been reported that BS cells have increased numbers of micronuclei possibly resulting from
persistent anaphase bridges breaking in late mitosis [10]. Studies have also implicated a role for
BLM in telomere maintenance, with BS cells exhibiting slower telomeric replication [11-14].
Loss of BLM therefore leads to the failure of cellular mechanisms which maintain chromosomal
stability. The immortalized BS patient derived cell line GM08505 is aneuploid. The potential
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conundrum is whether the chromosomal instability phenotype is partly due to its ploidy or if it is
aneuploid because of chromosomal instability.
Chromosomal instability and aneuploidy have been considered hallmarks of cancer cells
and tumorigenesis [15, 16]. Chromosomal instability is a form of genomic instability and
pertains to gain or loss of either whole chromosomes or chromosomal segments. Compared to
normal cells, such events occur at a higher frequency in cancer cells [17]. Defects in DNA
replication, telomere maintenance, chromosomal segregation, cell cycle checkpoint activation,
and DNA damage response are some of the most critical cellular causes of chromosomal
instability. Aneuploidy is an uneven chromosome number, and co-exists with and is considered
to be an outcome of chromosomal instability [16-19]. Paradoxically, another school of thought
considers aneuploidy as the driver of chromosomal instability [16, 20, 21]. It has been suggested
that variable expression of genes on aneuploid chromosomes can potentially disrupt the function
of their protein product, leading to chromosomal instability phenotypes [22]. Further adding to
the complex relationship, it has been shown that aneuploidy is a deterrent to tumorigenesis [23].
To reconcile their co-existence in cancer cells, it has been proposed that chromosomal instability
and aneuploidy are part of a vicious cycle, where one fuels the other and the end result is an
increasingly diverse karyotype. This variation resulting from aneuploidy can directly impact
gene expression [24].
In this study, we generate a diploid BLM knockout cell line to determine the impact of
aneuploidy on cellular defects associated with loss of BLM function.
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MATERIALS AND METHODS
Cell lines, plasmid constructs and transfections
GM08505 is an SV40-transformed skin fibroblast cell line (FCL) established from a
patient with Bloom syndrome (Coriell Cell Repository). GM00637 is an SV40-transformed FCL
from a non-Bloom syndrome individual (Coriell Cell Repository). Cells were grown in minimal
essential medium (Corning) supplemented with 10% FBS and 2 mM glutamine at 37°C in the
presence of 5% CO2. GM08505 cells were plated 24 hr before transfections at approximately 2 ×
104 per cm2. BLM cDNA cloned into pcDNA3 vector and mutated at stated sites was transfected
by using Polyfect (Qiagen) according to the manufacturer’s instructions. Stable clones were
selected in the presence of 750 μg of G418 per ml. Clones were maintained in the presence of
350 μg of G418 per ml. BLM cDNA contained in pcDNA3 vector was a kind gift from Dr Ian
Hickson, University of Copenhagen.
CRISPR/Cas9-mediated BLM knockout
A diploid BLM knockout cell line was derived from the GM00637 cell line using a
CRISPR/Cas9 mediated genome engineering protocol [25]. Briefly, guide or gRNA sequences
targeting exon 8 within BLM were designed using the CRISPR guide design tool, which
identifies and ranks suitable target sites and predicts off-target sites for each intended target
(http://tools.genome-engineering.org). gRNA sequences with the highest score and least offtarget impacts were cloned into the pSpCas9(BB)-2A-Puro vector and transfected into GM00637
using Lipofectamine 2000 (Invitrogen). Selection and clonal isolation was performed in the
presence of 0.125 µg/mL puromycin. Amplicons were generated to sub-clone BLM exon 8
genomic loci into pCR-TOPO II vector for verification by sequencing. The protein consequences
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of frameshift mutations within clones KSVS1452 and KSVS1453 are described in Table 3.1.
Further verification was carried out by immunoblotting.
Antibodies
Mouse monoclonal antibody BLM-(F5) (Santa Cruz Biotech) was used to detect BLM.
Rabbit polyclonal antibody against γ-H2AX (PhosphoDetect Anti-H2AX [pSer139]; Upstate
Cell Signaling Solutions) was used for the γ-H2AX accumulation assays. Rabbit polyclonal antihistone H3 and mouse monoclonal anti-tubulin antibodies (Abcam) were used to validate loading
and quantify fold changes.
Subcellular fractionation and immunoblotting
Nuclear extract were prepared from exponentially growing cells to detect BLM
expression in vivo. Briefly, cells were lysed (20 mM Tris pH 7.4, 10 mM KCl, 1 μM EDTA,
0.2% NP40, 50% glycerol, 0.6 mM βME, 1 mM PMSF and protease inhibitor cocktail) for 2 min
on ice, which was followed by nuclear extraction (20 mM Tris pH 7.4, 10 mM KCl, 0.4 M NaCl,
1 μM EDTA, 50% glycerol, 0.6 mM BME, 1 mM PMSF and protease inhibitor cocktail) for 30
min on ice. For the γ-H2AX accumulation assays, chromatin fractions were extracted from the
nuclear extract pellet by using an acid extraction buffer (0.5 M HCl, 50% Glycerol, 100 mM
βME) and subsequently neutralized using 40 mM Tris pH 7.4 with protease inhibitors and NaOH
[26].
SCE analysis
SCEs were analyzed by using protocols described previously [27-29]. Briefly, cells were
cultured for two cell cycles in growth medium supplemented with BrdU Labeling Reagent (Life
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Technologies) at a dilution of 1:100. Metaphase arrest was induced by the addition of 0.1 μg/ml
Colcemid for 1 hr before harvesting. Chromosome spreads were prepared after hypotonic
treatment with 75 mM KCL and fixation with 3:1 (vol/vol) methanol-acetic acid. The metaphase
spreads were then differentially stained using Hoechst 33258 (75µg/ml; Life Technologies) and
Giemsa (3.5%; Life Technologies). Intact metaphases were imaged using the Plan-Apochromat
100x/1.40 Oil DIC M27 objective of a Zeiss Axiovert 100 deconvolution microscope. For each
cell line, SCEs in >1500 chromosomes were scored.
Clonogenic cell survival assay
Cells were seeded at a density of 500 cells/well for colony formation. The next day,
either fresh medium containing HU (0.1, 0.2, 0.3, 0.4 and 0.5 mM HU) or drug-free medium was
added. The medium was removed after 48 hr and cells were washed with PBS before colonies
were allowed to grow in fresh complete growth medium for up to 4 weeks. Colonies were fixed
in 3:1 (vol/vol) methanol-acetic acid and stained with 0.01% crystal violet. Colonies with more
than 50 cells were scored as survivors. The number of colonies at each dosage point was
expressed as a percentage.
γ-H2AX accumulation assay
Exponentially growing cells were treated with 1μM CPT and harvested post release from
treatment at various time points (10 min, 20 min, 30 min, 45 min, 1 hr, 8 hr, 24 hr and 48 hr).
Chromatin fractions were run on a 16% Tricine-SDS polyacrylamide gel [30] and Western blots
were probed with anti- γ-H2AX antibody (PhosphoDetect Anti-H2AX [pSer139]). Fold changes
in γ-H2AX levels with respect to histone H3 levels were obtained using ImageJ [31].
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Neutral comet assay
Neutral Comet assays were performed according to protocols described earlier [32, 33].
Briefly, damage was induced by the addition of 1 μM CPT to culture for 1 hr. Subsequently, the
cells were grown in drug-free media for 1, 24 and 48 hr before being harvested. Single cell
suspensions in 1% low melt agarose were plated on slides, lysed using neutral lysis buffer and
electrophoresed at 25 V for 30 mins. The slides were immersed in 70% ethanol for fixation and
subsequently stained using SYBR Gold (1:10,000 in PBS; Life Technologies). At least 50
comets were imaged for each clone at each time point and the mean of the tail DNA percentage
was calculated using OpenComet, an open source software for automated analysis of comet
assay images [34].
RESULTS
Indels in BLM exon 8 result in premature termination of BLM before motif IV of its
helicase domain
We used diploid GM00637 cells, which have no known BLM deficiency or dysfunction,
as the target of CRISPR/Cas9 mediated genome engineering to generate a diploid, functional
BLM knockout cell lines. Indel events and single amino acid residue changes within the
conserved helicase domain of BLM interfere with its helicase function, resulting in a complete
loss of function [35-37]. Therefore, we chose to engineer indels within BLM exons 6-8 in order
to induce frameshift mutations potentially resulting in premature termination of BLM either just
before or at the beginning of its helicase core region. Based on an experimental design
previously shown to be efficient [25], we designed multiple short guide or sgRNA sequences to
enable CRISPR/Cas9 mediated indel events to occur within exons 6-8 and proceeded to
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functionally screen clonal isolates (Figure 3.1.A and Table 3.1). Two of the exon 8 targeted
clones did not show any signal upon immunoblotting to test for BLM expression (Figure 3.1.B).
Sequencing the targeted exon 8 loci further revealed biallelic modifications within these two
clones. The first clone, now designated KSVS1452 contained a 7 bp deletion in one allele and a
6 bp deletion/2 bp insertion in the other allele. The other clone, now designated KSVS1453,
contained a 4 bp deletion/2 bp insertion in one allele and a 5 bp deletion/3 bp insertion in the
other allele. Both allelic modifications in KSVS1452 resulted in BLM terminating at residue
686, whereas the allelic modifications in KSVS1453 resulted in BLM terminating at residues 676
and 682 (Figure 3.1.C and Table 3.2).
KSVS1452 and KSVS1453 are diploid and exhibit elevated SCE levels
We performed a karyotype using KSVS1452 and KSVS1453 cells to ascertain their
ploidy. 35 metaphase spreads from each cell line were stained with Giemsa and ~1500
chromosomes were counted. Both the cell lines were found to be diploid (Figure 3.2.A). Since
highly elevated levels of SCE are a hallmark of BLM-/- cells, we measured the SCE rates in
KSVS1452 and KSVS1453 cells as our primary functional test. The cells were labeled with
BrdU for two cell cycles and used to prepare metaphase spreads. These were differentially
stained with Hoechst/Giemsa and SCEs from ~1500 chromosomes were scored. We found a 15fold and 10-fold increase in the SCE frequencies in KSVS1452 and KSVS1453 cells compared
to GM00637 cells (Figure 3.2.B and C). This is consistent with SCE frequencies observed in BS
patient derived cells as well as BLM-/- cells expressing variants which have a null phenotype [36,
38].
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KSVS1452 and KSVS1453 cells are hypersensitive to replication stress induction
and exhibit reduced DSBR efficiency
BLM-/- cells and cells expressing BLM null variants are hypersensitive to the replication
stress inducing drug hydroxyurea (HU) and the Top I poison camptothecin (CPT) [36]. To test
their response to genotoxicity, cells were exposed to various concentrations of HU for 48 hrs
before being released into drug free media and stained to score surviving colonies after 4 weeks.
Both the cell lines exhibited increased sensitivity to HU compared to GM00637 cells (Figure
3.3).
Next, we induced replication-specific DSBs by growing the cells in the presence of
0.1µM CPT. Phosphorylation of histone H2A at Ser139 to form γ-H2AX is one of the earliest of
markers of DSB formation [39]. Therefore, we measured accumulation of γ-H2AX in cells from
various time-points post-CPT treatment release as an index of replication stress response
initiation. Using a phospho-specific antibody recognizing γ-H2AXpSer139 for immunoblotting, we
found that γ-H2AX accumulation in KSVS1452 and KSVS1453 cells peaked at 24 hr post-CPT
release compared to 1 hr in GM00637 cells. Furthermore, γ-H2AX was eliminated rapidly in
GM00637 cells after peaking as opposed to KSVS1452 and KSVS1453 cells (Figure 3.4).
Apart from being the one of the first DSB formation markers, γ-H2AX has also been
implicated in recruiting DSB repair factors and maintaining replication stress response [40-42].
The remarkable disparity in γ-H2AX accumulation and elimination profiles between GM00637
and KSVS1452/KSVS1453 cells is similar to differences observed when comparing
GM00637cells, BS patient derived cells and cells expressing BLM variants with a null
phenotype [36]. As shown earlier, this impaired γ-H2AX accumulation/elimination corresponded
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to inefficient DSBR. Therefore, we used a neutral comet assay to test the DSBR efficiency of
KSVS1452/1453 cells. Cells were exposed to 0.1µM CPT and harvested at the same time-points
used for testing γ-H2AX accumulation. Single cell suspensions were lysed and used for
electrophoresis. At the end of 24 hrs, 14% of DSBs were unrepaired in GM00637 compared to
65% and 45% in KSVS1452 and KSVS1453 cells respectively (Figure 3.4).
DISCUSSION
In this study, two clonal isolates of a diploid fibroblast cell line with indels engineered
within exon 8 of the BLM gene resulted in two functional BLM knockout cell lines. Remarkably,
these cell lines exhibit cellular defects consistent with those observed in immortalized BS patient
derived cells and cells expressing helicase dead or null mutants of BLM [36]. The BS patient
derived cell line, GM08505, is aneuploid and some of the chromosomal instability phenotype
could be attributed to its ploidy. We show that these cellular defects are directly associated with
loss of BLM function. Despite being diploid, cells lacking functional BLM exhibited defects in
cellular pathways associated with maintaining chromosomal stability. It remains to be seen
whether this chromosomal instability would lead to aneuploidy in these two cell lines as they
continue to be passaged and could shed more light on this relationship. SCE levels in BS patient
derived cell lines have been shown to be restored to near normal levels by BLM
complementation, presenting a system for structure-function analysis by complementing various
BLM variants [36, 38]. It is interesting to note that the elevated SCE frequencies observed in
these cell lines were comparable to that of BS patient derived cell line despite very little
adaptation time. Based on our results, we propose that CRISPR/Cas9 mediated genome
engineering can be used to generate compound heterozygous BLM mutant cell lines to
understand the function of BLM in maintaining chromosomal stability.
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Hypersensitivity to replication stress inducing agents and reduced DSBR efficiency in the
two knockout cell lines provide additional evidence of BLM function in the response to
replication induced DSBs. Specifically, delayed γ-H2AX accumulation and elimination suggest a
direct role for BLM as an early DSB responder/recognizer during replication. This data also
strengthens the association between BLM function and γ-H2AX dephosphorylation [36].
One approach to understand pathways compensating for/compounding defects associated
with BLM deficiency is to perform a quantitative global proteome evaluation to identify
dysregulated factors. However, the BS patient derived cell line GM08505 is aneuploid with a
variable chromosome number. This can potentially lead to variable gene dosage and differential
protein levels within the cell line. There is evidence of aneuploidy can directly affect gene
expression and lead to a variable proteome levels [24]. Therefore, aneuploid cell lines are not
conducive to be used for evaluating proteomes quantitatively. The two diploid BLM knockout
cell lines generated in this study can now be used for a comparative quantitative proteomic
approach to identify dysregulated factors. Additionally, these diploid cell lines provide a system
to complement and study BLM function in the absence of potentially dysregulated factors in the
aneuploid GM08505 cell line.
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FIGURES AND TABLES
Table 3.1. Primers and gRNAs used in this study
Oligo ID
3119BLM_E6sgRNA_F
3120BLM_E6sgRNA_R
3121BLM_E7sgRNA_F
3122BLM_E7sgRNA_R
3124BLM_E8sgRNA_F
3125BLM_E8sgRNA_R
3131pSpCas9_Chk-1
3132pSpCas9_Chk-2
3133pSpCas9_Chk-3
3134pSpCas9_Chk-4
3135pSpCas9_Chk-5
3136pSpCas9_Chk-6
3137pSpCas9_Chk-7
3138pSpCas9_Chk-8
3139pSpCas9_Chk-9
3140pSpCas9_Chk-10
3164BLMEx6-1_F
3165BLMEx6-1_R
3166BLMEx7-1_F
3167BLMEx7-1_R
3168BLMEx8-1_F
3169BLMEx8-1_R
3170BLMEx7-2_F
3171BLMEx7-2_R
3172BLMEx8-2_F
3173BLMEx8-2_R
3174BLMEx6-2_F
3175BLMEx6-2_R

Sequence
CACCGGGAACGAACTGCTTCAGCAG
AAACCTGCTGAAGCAGTTCGTTCCC
CACCGTTCACTTGATGGCCCTATGG
AAACCCATAGGGCCATCAAGTGAAC
CACCGGCGATCAATGCTGCACTGCT
AAACAGCAGTGCAGCATTGATCGCC
GGTATCCACGGAGTCCCAG
GGACAGCACCGACAAGGC
CAAGAACCTGTCCGACGC
CCTTCCGCATCCCCTACTAC
CCACGATCTGCTGAAAATTA
GAGCTCGTGAAAGTGATGGG
TTCGACAATCTGACCAAGGC
CAAGACCGAGATTACCCTGG
CCTGATCATCAAGCTGCCTA
ACCCTGATCCACCAGAGCAT
GCTAGACAGATAAGTTTACAGCAGC
ATGATCATCCTTATGCCATTTCCAG
ACCACTCTAAGTGAAAAATGGACAG
TATCATAGGAAGGTTGGGTTTCTCT
AAAGTAGTGGTAGGTGCTGTAGAAA
GTTGCAAATAAACTGCCAGAAATGG
ACTACAGATTTGCTTTTGTGGCCTA
CCAGTTGCTACTTACAAAGGACTTCT
GCTGTACTTTCACTGTATTCATGTACT
CTTTCTCACTATGGTACAGGAGGTT
TTACAGTCATGAGCCACCATGC
ACGAATGTTAAAGGAGTGGTTTGAA
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Table 3.2. Consequences of targeted frameshift mutations within BLM exon 8

Cell line

BLM
genomic
consequence

GM00637

KSVS1452

KSVS1452

KSVS1453

KSVS1453

BLM amino acid
sequence

BLM protein
consequence

DKSAQNLASRNLKH
ERFQSLSFPHTKEM
MKIFHKKFGLHNFR
TNQLEAINAALLGE
DCFILMPT
BLM exon 8
(c.del2040_2
046;
g.del90,763,1
23_90,763,13
0)
BLM exon 8
(c.delins2036
_2041AG;
g.delins90,76
3,119_90,763
,124AG)
BLM exon 8
(c.delins2039
_2042AC;
g.delins90,76
3,122_90,763
,125AC)
BLM exon 8
(c.delins2025
_2029GTA;
g.delins90,76
3,108_90,763
,112GTA)

DKSAQNLASRNLKH
ERFQSLSFPHTKEM
MKIFHKKFGLHNFR
TNQLEAINAALKTV
LS

BLM
(p.Leu681Lys
Ter686)

DKSAQNLASRNLKH
ERFQSLSFPHTKEM
MKIFHKKFGLHNFR
TNQLEAINAELVKT
VLS

BLM
(p.Leu678Ala
Ter686)

DKSAQNLASRNLKH
ERFQSLSFPHTKEM
MKIFHKKFGLHNFR
TNQLEAINAALH

BLM
(p.Leu678HisT
er682)

DKSAQNLASRNLKH
ERFQSLSFPHTKEM
MKIFHKKFGLHNFR
TNQLEA

BLM
p.(676IleTer*)
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BLM
Tubulin

C

GM00637+pSpCas9sgRNAEx8 Clonal
Isolates

BLM
Tubulin

C

Figure 3.1. CRISPR/Cas9 mediated BLM knockout
Schematic representation of protocol used to generate CRISPR/Cas9 mediated BLM knockout
cell lines (A). Immunoblot showing absence of BLM signal; Clone 6 is KSVS1452 and clone 4
is KSVS1453 (B). 2-D map of BLM showing the protein consequences of BLM after indels were
engineered in exon 8 (C).
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Figure 3.2. Chromosomal aberrations in BLM knockout cell lines
KSVS1452 and KSVS1453 cells are diploid (A). KSVS1452 cells showing SCEs characteristic
of BS cells (B). SCEs scored from ~1500 chromosomes show elevated SCE frequencies in
KSVS1452 and KSVS1453 compared to the parental GM00637 cell line.
100

GM00637
KSVS1452
KSVS1453

Survival (%)

80

60

40

20

0
0.0

0.1 0.2 0.3 0.4
Hydroxyurea (mM)

0.5

Figure 3.3. KSVS1452 and KSVS1453 exhibit hypersensitivity to hydroxyurea
Cells were exposed to hydroxyurea and surviving colonies were scored four weeks after relase
from treatment.
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Figure 3.4. Response to replication stress induced double strand breaks
KSVS1452 and KSVS1453 cells exhibit delayed response to replication stress with a
concomitant decrease in DSBR efficiency.
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CHAPTER FOUR:
CELL CYCLE SPECIFIC INTERACTIONS WITH MCM6 UNCOVER A NOVEL ROLE
FOR BLM IN GENOME STABILITY
Note to reader: Unpublished data. Experiments were designed by Kristina H. Schmidt and Vivek
M. Shastri. All experiments were performed by Vivek M. Shastri.
SUMMARY
The Bloom syndrome DNA helicase BLM contributes to chromosome stability through
its roles in double-strand break repair by homologous recombination (HR), suppression of
recombination at Gquadruplexes, and DNA replication fork restart during the DNA-damage
response. Here, we report that BLM physically interacts with the Mcm6 subunit of the replicative
MCM helicase and that this interaction is mediated by two distinct bindings sites in BLM and
Mcm6 that differentially regulate BLM/MCM interaction in G1 and in normal or perturbed Sphase. Unlike other replisome components, BLM binds to the Cdt1-binding domain of Mcm6
and can compete with Cdt1 for Mcm6 binding in G1. We demonstrate the significance of BLM
and the novel BLM/Mcm6 interaction for unfolding G-quadruplex structures in G1 phase,
suggesting that the BLM/Mcm6 interaction contributes to genome stability by assisting
replisome assembly and initiation at G-quadruplex-rich origins.
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INTRODUCTION
Genomic instability is a hallmark of disorders in which DNA repair genes are
dysfunctional (Zeman and Cimprich, 2014). The prevention of genomic instability also depends
on multiple pathways ensuring timely progression of replication and appropriate response to
DNA damage. The tumor suppressor gene BLM encodes a 3’-5’ DNA helicase of the conserved
RecQ DNA helicase family, which has been implicated in key roles during DNA recombination
and repair to maintain genome stability (Bachrati and Hickson, 2003, Hickson, 2003, Karow et
al., 1997, Ouyang KJ et al., 2008). Null mutations in BLM cause Bloom syndrome (BS), an
autosomal recessive disorder characterized by short stature, an extreme predisposition to a wide
range of cancers from an early age and, at the cellular level, elevated levels of sister chromatid
exchanges (SCEs), chromosome aberrations and hypersensitivity to DNA-damaging agents
(Chaganti et al., 1974, German, 1998, German et al., 2007). The best understood function of
BLM is the dissolution of double Holliday junctions during HR-mediated DNA double strand
break (DSB) repair where BLM acts in a complex with TopoIIIα, Rmi1 and Rmi2 to yield
noncrossover products (Karow et al., 2000, Wu and Hickson, 2003). BLM also controls early
steps of HR by contributing to the processing of DSB ends into single stranded 3’ overhangs for
strand invasion and through its ability to reverse the strand invasion step (Daley et al., 2014).
BLM helicase function is also required for efficient restart of stalled replication forks in
the presence of replication stress. In the absence of BLM, cells exposed to replication-stressinducing agents like hydroxyurea (HU) display compromised fork reactivation and delayed cell
division (Sidorova et al., 2013). Of all stalled replication forks, fewer than 40% restart in BS
cells (Davies et al., 2007). Studies have shown BLM localization to stalled replication forks that
develop into DSBs (Davalos and Campisi, 2003). Chromatin recruitment of DNA-damage114

response factors like BRCA1, 53BP1 and the MRN complex to stalled replication forks is
delayed in BS cells, leading to BLM being associated with a role in their recruitment and
facilitating fork protection (Davalos and Campisi, 2003, Franchitto and Pichierri, 2002). These
observations establish BLM as an important factor in the replication stress response.
BLM’s function in recombinational repair has been proposed as a plausible mechanism
by which it promotes fork restart upon replication stress induction. Notably, in vitro analyses
have shown that BLM can promote regression of model replication forks (Machwe et al., 2006,
Ralf et al., 2006). Moreover, the high level of SCEs in BS cells has been viewed as possible
evidence of illegitimate mitotic recombination products when collapsed replication forks
undergo DSB repair (Wu et al., 2001).
In vitro, BLM has been shown to bind and unwind G-quadruplex (G4) structures (Popuri
et al., 2008, Sun et al., 1998, Wu et al., 2015). In vivo, G4s are stable secondary DNA structures
that impede replication fork progression, especially at telomeres (Bochman et al., 2012, Lam et
al., 2013, Lopes et al., 2011). However, reports of a direct role of BLM in G4 unwinding in vivo
have remained sparse (van Wietmarschen et al., 2018). There is evidence of slow moving
replication forks originating within the G4- rich telomeric sequences in BS cells (Drosopoulos et
al., 2015). However, instead of BLM, other RecQ helicases, most notably WRN, appear to have
specialized in G4 unwinding during telomere replication, and defects in WRN lead to telomere
dysfunction and an adult premature aging syndrome (Werner syndrome) whereas BLM defects
do not (Kudlow et al, 2007). Further underscoring BLM’s specificity to a variety of noncanonical DNA substrates, BLM can also unwind model DNA:RNA hybrids and R-loops in
vitro, which can cause replication fork stalling (Grierson et al., 2012). Observations of R-loop
accumulation causing DNA damage in BS cells and BLM/R-loop proximity in vivo seem to
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imply BLM involvement in maintaining replisome stability at sites of collision with R-loops
(Chang et al., 2017).
The six-subunit minichromosome maintenance (MCM) complex is an essential
component of the eukaryotic replisome and functions in DNA replication initiation and
elongation. It is the catalytic subunit of the major replicative helicase complex and is loaded onto
DNA replication origins in a stepwise manner by the licensing factor Cdt1 (Evrin et al., 2009,
Liu et al., 2012, Remus et al., 2009). An excessive amount of the MCM complex is loaded onto
replication origins, but not all fire in the following S-phase. These so called dormant origins fire
under low levels of endogenous replication stress and may prevent DSBs forming from stalled
DNA replication forks (Ibarra et al., 2008). The MCM complex also serves as an important
component of the replication checkpoint and is an effector of the ATR– FANCD2–FANCI
pathway activated in response to replication stress (Chen et al., 2015, Cortez et al., 2004,
Lossaint et al., 2013, Yu et al., 2016). It is evident that the MCM complex has functions beyond
its role in duplex unwinding to safeguard genomic integrity. However, it requires assistance from
specialized DNA helicases to move through challenging loci containing non-canonical DNA
structures (Leman and Noguchi, 2013).
Here, we performed a proteomic analysis of the BLM complex in mid-S-phase to identify
the mechanism by which BLM contributes to stable genome duplication in unperturbed cells. We
identified the MCM subunit Mcm6 as a novel BLM interactor and show that BLM uses multiple,
distinct binding sites to differentially associate with Mcm6 during pre-initiation complex
formation in G1, at active replisomes in S-phase, and during the DNA-damage response. Unique
among replisome components, BLM binds to the Cdt1-binding domain of Mcm6 in S-phase and
competes with Cdt1 for Mcm6 binding in vitro and in G1 phase. Our findings reveal BLM as a
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constitutive component of active replisomes in unperturbed S-phase and uncover the importance
of BLM and the BLM/Mcm6 interaction in the absence of DNA replication in G1 phase when
G4s ubiquitously form at replication origins and may interfere with pre-replication complex
formation and the G1/S transition.
RESULTS
BLM forms a complex with Mcm6 in G1 and S-phase
To identify the composition of the BLM complex during unperturbed DNA replication,
we performed a proteomic screen in mid-S-phase when BLM expression peaks. We
synchronized GM00637 cells (BLM+/+, normal skin fibroblasts) in G1 phase, released them into
S-phase for 3 hours, immunoprecipitated endogenous BLM from nuclear extracts and identified
co-immunoprecipitates by mass spectrometry. Across three biological replicates, Mcm2, Mcm6,
and Mcm7 subunits of the MCM helicase were the top identified hits in addition to known BLM
interactors TopoIIIα (Wu et al., 2000), Rmi2 (Singh et al., 2008), and PML (Bischof et al., 2001)
(Fig. 1A). Of these, only Mcm6 was not identified in the isogenic BLM knockout cell line
(KSVS1452). We verified the BLM/Mcm6 interaction by reciprocal co-immunoprecipitation
using recombinant BLM and Mcm6 (Fig. 1B) and detected the interaction between endogenous
BLM and Mcm6 in GM00637 cells not only in S-phase, but also in G1 (Fig. 1C). As expected,
the interaction was not detected in the isogenic KSVS1452 cell line with a CRISPR-mediated,
biallelic disruption of exon 8 of BLM (Fig. 1C, Fig. S1A-G).
Using antibodies directed against endogenous BLM and Mcm6, we observed that BLM
forms foci in G1 and in S-phase and that all BLM foci colocalize with Mcm6 (Fig. 1D, 1F and
1G). The vast majority (95%) of Mcm6/BLM foci in unperturbed S-phase were at sites of active
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DNA replication as indicated by EdU incorporation (Fig. 1E and 1H). These findings suggest
that BLM is a component of pre-initiation complexes in G1 and a constitutive component of
active replisomes in unperturbed S-phase. Starting at mid-S-phase, occasional BLM foci
appeared that were not in the same complex as Mcm6 (Fig. 1G). These foci make up ~4-8% of
all BLM foci in the second half of S-phase and predominantly colocalize with PML (Fig. S1H),
suggesting that BLM may be sequestered to PML bodies as genome duplication nears
completion or where it may be modified and degraded (Ouyang et al., 2009, Singh et al., 2008).
Lack of colocalization with 53BP1 in unperturbed S-phase (Fig. S1I) suggests that most of these
BLM foci are not indicative of spontaneous DSBs in late S-phase.
BLM binds to the N-terminal domain of Mcm6 via a pseudo-PIP-box
The Mcm2-7 proteins, which make up the hexameric MCM complex, can be divided into
an Nterminal domain, which contains the oligonucleotide-binding (OB) domain, and a Cterminal domain, which contains the conserved ATPase core and an extension defined by a
winged-helix (WH) domain (Riera et al., 2017). In human Mcm6, the N-terminal domain spans
from residues 1-325 and the Cterminal domain spans residues 326-821. Using a mammalian twohybrid assay, we determined that BLM interacts with both of these Mcm6 domains (Fig. 2A,
2B). Dividing BLM into its two major domains– the disordered N-terminal tail (residues 1-647)
and the C-terminal helicase domain (residues 648-1417) (Fig. S2A) – we determined that the
interaction with the N- and the C-terminal Mcm6 segments occurred via the first 647 residues of
BLM. We narrowed down the binding site for the N-terminal segment of Mcm6 to residues 80120 of BLM (Fig. 2A, see also Fig. S2B). This disordered region in BLM contains the conserved
sequence 83QQRVKDFF90 (Fig. 2C), reminiscent of a PCNA-interacting protein (PIP) box
(Boehm and Washington, 2016). Mutating this sequence to AxxAxxAA (hereafter referred to as
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blm-QVFF), significantly reduced the two-hybrid interaction between Mcm6 and BLM, which
still contains the second Mcm6 binding site, was (Fig. 2E). Alanine substitution of other
hydrophobic residues in the 80-120 region of BLM, such as L107/L108 or F111, did not have a
significant effect on Mcm6 binding (Fig. S2D).
Prompted by the resemblance of the Mcm6-binding site to a PIP-box, we tested by
coimmunoprecipitation if the 83QQRVKDFF90 sequence also mediates an interaction between
BLM and PCNA. We did identify an interaction of PCNA with wild-type BLM, the blm-QVFF
mutant, and an Nterminal truncation of BLM that is missing the first 160 amino acids, but not
with a peptide of residues 1-120 of BLM (Fig. S2E). Thus, PCNA is indeed in a complex with
BLM, but the PIP-box-like Mcm6- binding site is not involved in PCNA binding.
A second site in BLM binds to the Cdt1-binding domain of Mcm6
In addition to the interaction with the N-terminal domain of Mcm6, we identified a
second interaction between the BLM N-terminal tail (residues 1-647) and the C-terminal domain
of Mcm6 (residues 325-821). Further dividing the Mcm6-C-terminal domain revealed a twohybrid interaction between BLM and residues 708-821 of Mcm6 (Fig. 2B, see also Fig. S2C),
which make up the winged helix (WH) domain that binds to Cdt1 and is required for MCM
loading at origins (Fernández-Cid et al., 2013, Zhang et al., 2010, Wei et al., 2010). BLM does
not bind to the ATP-ase domain of Mcm6 (Fig. 2B, residues 325-707) where most replisome
components bind Mcm6, including Cdc45, TIM, TIPIN, Claspin, RPA2, MCM-BP, Mcm10 and
Mcm4 (Hosoi A, 2015). In the two-hybrid assay, residues 708-821 of Mcm6 bound to residues
220-285 of BLM (Fig. 2B, see also Fig. S2C). The most striking feature in this disordered region
of BLM is a stretch of four hydrophobic residues embedded in an acidic patch, 235VICI238 in
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human BLM, that is conserved in mammals, birds and Xenopus (Fig. 2D). Two additional
hydrophobic residues nearby, W230 and L231, are conserved in mammals. Mutating the VICI or
WLVICI residues to alanine (blm-VICI, blm-WLVICI) significantly reduced the two-hybrid
interaction with Mcm6 (Fig. 2F).
Based on where BLM binds Mcm6, we termed the BLM region that binds the N-terminal
domain of Mcm6 and is disrupted by the QVFF mutation the Mcm6-N-terminal binding domain
(MBD-N) and the BLM region that binds the C-terminal domain of Mcm6 and is disrupted by
the WLVICI mutation the Mcm6-C-terminal binding domain (MBD-C).
MBD-N or MBD-C of BLM acts as G1- and S-phase-specific Mcm6 binding sites
Using co-immunoprecipitations from synchronized cells, we determined that wildtype
BLM and Mcm6 interact in unperturbed G1 and S-phase and after induction of replicationdependent DSBs by camptothecin (CPT) (Fig. 3A). Since BLM binds to the Cdt1-binding
domain of Mcm6, we also assessed the interaction between Mcm6 and Cdt1. As expected, Mcm6
and Cdt1 interacted in G1, but not in S-phase when Cdt1 levels decrease rapidly. Notably, we
also observed a rapid increase in Cdt1 levels in S-phase cells exposed to CPT (Fig. 3B) and the
re-establishment of the Mcm6/Cdt1 complex (Fig. 3A). Cdt1 levels decreased immediately upon
removal of CPT (Fig. 3B). Cdt1 levels in both, wildtype cells and BLM-deficient cells,
responded similarly to CPT (Fig. S3A).
The blm-QVFF mutant failed to bind Mcm6 in G1, but co-immunoprecipitated normally
with Mcm6 in S-phase, including after CPT treatment (Fig. 3C). In support of this G1-specific
defect of the QVFF mutation, we observed the same Mcm6-binding pattern for an N-terminal
truncation of BLM that removes the QVFF residues (blm-Δ160) and for the milder blm-QVF
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mutation, which retains minimal Mcm6 binding in G1 (Fig. S4A and S4B). Remarkably, the
blm-WLVICI (MBD-C) mutant had the opposite phenotype of the blm-QVFF (MBD-N) mutant.
It bound Mcm6 normally in G1, but poorly in S-phase, and not at all after exposure to CPT (Fig.
3D). The milder VICI mutation retained slightly more interaction with Mcm6 in S-phase and
after CPT treatment (Fig. S4C). Thus, BLM uses to two distinct sites - residues 83-90 (MBD-N)
and residues 231-238 (MBD-C) - to bind to Mcm6 in G1 and in Sphase, respectively.
We also noticed a conserved acidic patch with several hydrophobic residues
(291FDDDDYDTDF300) just downstream of MBD-C (Fig. 3E). Nearby serine 304 was previously
shown to be phosphorylated in S-phase where it is involved in binding TopBP1 (Blackford et al,
2015; Sun et al, 2017). We found that mutating F291/Y296/F300 to alanine (blm-FYF) had no
effect on TopBP1 binding to BLM in unperturbed S-phase, but reduced TopBP1 binding after
CPT exposure (Fig. S4D). Similar to TopBP1, blm-FYF immunoprecipitated with Mcm6 in
unperturbed S-phase, but lost most of its association after exposure to CPT (Fig. 3F). In contrast
to the BLM/Mcm6 interaction, however, the first 240 residues of BLM, which contain both
Mcm6 binding sites, were not sufficient for the BLM/TopBP1 interaction (Fig. S4E), thus
separating the TopBP1 and Mcm6 binding sites in BLM. The FYF mutation significantly
reduced the two-hybrid between BLM and Mcm6, and mutating both QVFF and FYF led to a
further reduction (Fig. 3G). Remarkably, the blm-QVFF-FYF double mutant completely failed to
immunoprecipitate Mcm6 in both G1 and S-phase (Fig. 3H). These observations suggest that in
unperturbed S-phase residues 83-90 (QVFF) and 291-300 (FYF) of BLM contribute to Mcm6
binding, but that binding through one of these sites is sufficient for BLM association with Mcm6
as long as the major BLM/Mcm6 binding site in S-phase, WLVICI (MBD-C), is intact.
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Importance of the BLM/Mcm6 interaction in replication stress response
G-quadruplexes (G4s) are secondary DNA structures which cannot be unwound by the
replicative helicase and impede replication fork progression (Bochman et al., 2012, Lopes et al.,
2011). There are currently three mammalian DNA helicases implicated in G4 unwinding in vivo:
BLM, WRN, and FANCJ (London et al., 2008, Mohaghegh et al., 2001b, Budhathoki et al.,
2014). The Werner syndrome helicase WRN is primarily associated with the replication of
telomeric DNA, leading to telomere dysfunction and premature aging seen in Werner syndrome
patients (Crabbe et al., 2004). BLM and FANCJ have been implicated in the replication stress
response at forks stalled at internal genomic sites, including those that form G4s (Cantor and
Nayak, 2016, London et al., 2008). Here, we found that BLM-deficient cells are hypersensitive
to the G4-stabilizing agent pyridostatin (PDS) and that the association of BLM with Mcm6 is
essential to resist PDS (Fig. 3I). Compared to KSVS1452 cells transiently expressing wildtype
BLM, cells transiently expressing BLM mutants that fail to interact with Mcm6 in either G1
(blm-QVFF) or S-phase (blm-WLVICI) exhibited significantly decreased survival at all
concentrations of PDS tested. Combining the blm-QVFF and blm-FYF mutations, which
completely disrupts BLM/Mcm6 association in both G1 and in S-phase, caused PDS
hypersensitivity greater than either single mutants and was comparable to cells not expressing
BLM (Fig. 3I), indicating a further role for the QVFF and FYF sites in stabilizing BLM/Mcm6
interaction in response to replication stress.
BLM mutants that interrupted the interaction with Mcm6 in both G1 (blm-QVFF) and Sphase (blm-WLVICI, blm- FYF, blm-QVFF-FYF) caused hypersensitivity to hydroxyurea (HU),
which causes replication stress (Fig. 3J). However, the blm-QVFF mutants exhibited a wildtype
phenotype at all but one of the HU concentrations tested.
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These findings suggest that the BLM/Mcm6 interaction is functionally significant in the
response to replication stress.
Requirement of BLM for timely resumption of replication after DSB induction
To evaluate the importance of the Mcm6/BLM complex for the response to
replicationdependent DSBs we monitored formation of foci containing BLM, Mcm6 and Cdt1
and their colocalization with EdU in unperturbed S-phase as well as during and after treatment
with CPT (Fig. 6 B and 6C, see also Fig. S3B). In unperturbed S-phase, the vast majority of
Mcm6 foci colocalized with EdU in BLM+/+ (94.7%) and BLMKO cells (95.8%) and there was no
significant difference in the number of replicating Mcm6 foci between BLM+/+ and BLMKO cells
(p=0.41, Fig. 6). BLM+/+ and BLMKO cells responded similarly to CPT exposure, with a
significant increase in the number of nonreplicating Mcm6 foci, as indicated by Mcm6 foci that
do not colocalize with EdU, accompanied by a significant decrease in the number of active
replisomes (Fig. 6A). However, 45 minutes after CPT exposure we observed significantly fewer
replicating Mcm6 foci in BLMKO cells (26% of all Mcm6 foci) than in wildtype cells (62% of all
Mcm6 foci) (p<0.0001, Fig. 6C), suggesting that BLM is important for timely resumption of
DNA replication after DSB induction.
G1-specific BLM/Mcm6 association via MBD-N suppresses Mcm6/Cdt1 complex
formation
We showed above that BLM forms discrete foci in G1 and that all of these BLM foci
colocalize with Mcm6. The QVFF mutation, both in the QVFF single mutant and in the QVFFFYF double mutant, decreased BLM/Mcm6 colocalization and led to the appearance of BLM
foci that did not colocalize with Mcm6 (Fig. 4A, see also Fig. S6B). Surprisingly, as the number
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of Mcm6/BLM foci decreased, the number of Mcm6/Cdt1 foci increased in the QVFF mutants
(Fig. 4A). We determined that of all Mcm6 foci in the QVFF and QVFF-FYF mutants, 72-75%
colocalized with Cdt1 foci, which was similar to cells lacking BLM (82%) (Fig. 4B). In contrast,
in wildtype cells and in the WLVICI and FYF mutant, where the BLM/Mcm6 association in G1
is intact, only 42-48% of Mcm6 foci colocalized with Cdt1 (Fig. 4B).
These observations suggest an inhibitory effect of BLM and the BLM/Mcm6 interaction
on the association of Cdt1 with Mcm6 in G1. In support of this hypothesis, less Cdt1 coimmunoprecipitated with Mcm6 in cells expressing wildtype BLM than in cells expressing the
blm-QVFF mutant or no BLM (Fig. 4C).
To further test if BLM and Cdt1 can compete for Mcm6 binding we used
coimmunoprecipitations of the recombinant proteins (Fig. 4D, see also Fig. S5). Indeed, addition
of increasing amounts of BLM (0.5 – 1.5 pmol) to a mixture of equimolar amounts of Mcm6 and
Cdt1 (0.5 pmol) weakened the Mcm6/Cdt1 interaction in a dose-dependent manner, suggesting
that BLM can weaken the Mcm6/Cdt1 complex (Fig. 4D). We found that the reverse was also
true; adding increasing amounts of Cdt1 (0.5 – 1.5 pmol) disrupted the interaction between
Mcm6 and BLM, indicating that Cdt1 interferes in BLM/Mcm6 complex formation (Fig. 4D).
S-phase specific BLM/Mcm6 interaction via MBD-C and FYF residues is required
for the DNA damage response
Consistent with co-immunoprecipitations, disrupting MBD-C by the WLVICI mutation
led to the accumulation of BLM and Mcm6 foci that do not colocalize in unperturbed S-phase
cells (Fig. 4E). Remarkably, even though Mcm6 and Cdt1 do not interact in S-phase, we
observed occasional Mcm6/Cdt1 foci in the blm-QVFF mutant, supporting the possibility that
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the BLM/Mcm6 interaction via MBD-N inhibits the Mcm6/Cdt1 interaction. In contrast to the
blm-WLVICI and blm-QVFF mutants, the blm-FYF mutant still exhibited a wildtype phenotype
in unperturbed S-phase.
After exposure to CPT (Fig. 4F), we observed that wildtype cells responded with the
formation of BLM/Mcm6/Cdt1 foci, which became the predominant foci type. Interestingly, the
roles of the MBD-N and MBD-C binding sites in the DNA-damage response were reversed: the
blm-QVFF mutant, which had significant defects in G1, showed a wildtype distribution of foci
types and numbers with only a mild decrease in BLM/Mcm6/Cdt1 foci. In contrast, the blm-FYF
mutations inhibited the formation of BLM/Mcm6/Cdt1 foci and the blm-WLVICI mutation
completely abrogated it (Fig. 4F).
After exposing wildtype cells to CPT, we also noticed that ~25% of BLM foci no longer
colocalized with Mcm6 (Fig. 4F); instead they associated with 53BP1, suggesting that some
BLM relocalizes to DNA damage foci (Fig. S6A). This fraction of BLM foci that did not
colocalize with Mcm6 increased after CPT exposure especially in the blm-FYF and blmWLVICI mutants, making up 56% and 92% of all BLM foci, respectively (Fig. 4F, see also Fig.
S6C and S6D).
Since co-immunoprecipitations suggested that the BLM/Mcm6 interaction affects the
Mcm6- Cdt1 interaction, we also monitored foci formation in the blm-QVFF-FYF mutant,
finding that it completely failed to form foci with Mcm6 in G1, unperturbed S-phase, and after
CPT exposure, exhibiting a similar foci pattern as cells not expressing BLM (Fig. 4A, 4E and
4F). This observation is consistent with the failure of blm-QVFF-FYF to co-immunoprecipitate
with Mcm6 in unperturbed S-phase and suggests cooperation between MBD-N and the FYF
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residues in Mcm6 binding in unperturbed S-phase, with one site being sufficient for binding
BLM to Mcm6 as longs MBD-C is intact. That the WLVICI residues in MBD-C are essential for
association of BLM with Mcm6 in S-phase (Fig. 4C and Fig. 5B) further suggests that sites that
are essential for the association of BLM with Mcm6 in G1 (QVFF) and after CPT (FYF), can
contribute to BLM/Mcm6 binding in S-phase, but are secondary to the association of BLM with
Mcm6 via the WLVICI residues.
DISCUSSION
In this study, we have identified a direct physical interaction of BLM with the MCM
helicase subunit Mcm6 at active replisomes in S -phase and at inactive pre-initiation complexes
in G1. We demonstrate that this BLM/Mcm6 interaction in the two cell-cycle phases is mediated
by two distinct binding sites in the disordered N-terminal tail of BLM, one of which binds to the
N-terminus of Mcm6 in G1-phase and one that binds to the Cdt1-binding domain of Mcm6 in Sphase. We also show that BLM can compete with Cdt1 for Mcm6 binding in vitro and that BLM
and the BLM/Mcm6 interaction in G1 phase weaken Cdt1/Mcm6 complex formation in vivo.
Our finding that BLM uses distinct Mcm6 binding sites in G1 and in S-phase indicates
that the BLM interactions with Mcm6 in G1 and in S-phase are functionally significant. BLM is
not simply being loaded into the replisome in G1 as the blm-QVFF mutant, whose interaction
with Mcm6 in G1 phase is severely impaired (50%), can still associate with BLM at near
wildtype levels (90%) in S-phase, suggesting that BLM can associate with Mcm6 in S-phase
independently of its prior association with Mcm6 in G1. This raises the question of what role the
BLM/Mcm6 association plays during active replication in S-phase that extends to inactive
replisomes in G1. Based on BLM’s established functions in DNA repair by homologous
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recombination, it could be suggested that BLM associates with active replisomes in S-phase to
be instantly available for the repair of collapsed or stalled forks. Indeed, we observed that the
strength of the BLM/Mcm6 association after CPT treatment depended on the ability of BLM to
associate with Mcm6 in unperturbed S-phase (Fig. 5B and 5C, see also Fig. S6C and S6D).
However, such a role of the BLM/Mcm6 interaction is unlikely to extend to G1 phase when
replication is inactive.
One threat that active replisomes in S-phase and the formation of pre-initiation
complexes in G1 have in common are G4 structures. Sequences capable of forming G4s are
dispersed throughout the human genome and, importantly, have been identified at over 90% of
origins of replication in the human genome (Rhodes and Lipps, 2015). In fact, the most efficient
origins are CpG islands, which make up a third of all origins in the human genome (Cadoret et
al., 2008, Sequeira-Mendes et al., 2009). Sequences with the potential to form G4 structures
appear to play a ubiquitous and positive role in replication initiation (Prioleau and MacAlpine,
2016, Rhodes and Lipps, 2015, Valton and Prioleau, 2016). However, the current model of preRC formation in G1 and pre-IC formation at the G1/S transition does not include a DNA helicase
capable of G4 unwinding. The evolutionarily conserved RecQ family of DNA helicases has
several members with excellent G4-unwinding activity, most prominently BLM and WRN
(Budhathoki et al., 2014, Mohaghegh et al., 2001a), but their functions have not been implicated
in G1. Another RecQ-like helicase, RecQL4, is required for the initiation of DNA replication in
human cells (Sangrithi et al., 2005) and appears to have an N-terminal domain that allows it to
bind G4 structures (Keller et al., 2014). However, RecQL4 lacks the conserved RQC domain that
enables BLM and WRN to unwind G4s, and RecQL4 is unable to unwind G4s in vitro (Singh et
al., 2012).
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The increased PDS sensitivity of BLM-deficient KSVS1452 cells expressing the blmQVFF mutant, which interrupts BLM/Mcm6 interaction specifically in G1, indicates a possible
role for the BLM/Mcm6 association in G1 that could be explored in the future. Based on BLM’s
exquisite ability to bind and unfold G4 structures, one role we could envisage is the unfolding of
G4 structures that were recently proposed to form at origins of replication (Prioleau and
MacAlpine, 2016, Rhodes and Lipps, 2015) or DNA-structure unwinding during the G1/S
transition. However, PDS has also been shown to inhibit BLM’s ability to unwind duplex DNA,
suggesting that the cause for PDS hypersensitivity of the blm-QVFF mutant may not be limited
to G4-unfolding (Li et al., 2001). Thus, further investigations are required to verify a potential
role of BLM and the BLM/Mcm6 interaction in G1. For example, with a DNA combing assay
using BLM+/+ and BLM-/- cells, we will test if disruption of the BLM/Mcm6 association leads to
less efficient origin firing (Marheineke and Hyrien, 2004, Patel et al., 2006). We will also
quantify G4 structures in real-time during progression from G1 to S-phase in BLM+/+ and BLM-/cells as well as blm mutants using the new G4-specific fluorescent probe IMT (Zhang et al.,
2018). Furthermore, we will perform immunofluorescence analyses to reveal the timing of the
BLM/Mcm6 association in G1, specifically during pre-RC/pre-IC formation and the G1/S
transition. As an alternative to an enzymatic role of BLM in G1, the association of BLM with
Mcm6 in G1 could simply serve to load BLM into the replisome for a later function at the
replisome in S-phase. There, BLM could assist the CMG helicase to unwind unusual DNA
structures, such as G4s, during unperturbed growth, or be present to respond to replication stress.
Taken together, we propose the following model for BLM function and the BLM/Mcm6
interaction in G1 and unperturbed S-phase (Fig. 5): In G1, prior to the initiation of replication,
BLM is recruited to origins by binding to Mcm6. At this stage, MBD-N of BLM binds the N128

terminal domain of Mcm6, but does not engage with the C-terminal Cdt1-binding domain of
Mcm6. This arrangement may be necessary because Cdt1 is still bound to Mcm6 for the
recruitment of MCM hexamers to the origin recognition complex ORC (Chen and Bell, 2011,
Chen et al., 2007), thus making this site unavailable to the MBD-C site within BLM. Most
replication factors that interact with Mcm6 and are thought to regulate the MCM helicase do so
via the central ATPase domain, including Cdc45, RPA2, TIM, TIPIN, MCM10 and MCM-BP
(Hosoi et al., 2015). That BLM binds to the two domains upstream and downstream of the Mcm6
ATPase domain suggests that the BLM/MCM interaction is unlikely to interfere in other MCMprotein interactions that are critical for the formation of the pre-initiation complex. Although
dispensable for BLM/Mcm6 interaction in S-phase, we suggest that BLM association with MCM
via MBD-N in G1 plays a functionally significant role which will be unraveled by further
investigations.
In S-phase, Cdt1 is no longer bound to Mcm6 (Fig. 4E) and is degraded to prevent
relicensing of origins (Arias and Walter, 2006, Jin et al., 2006, Nishitani et al., 2006) (see also
Fig. S3A). Thus, in S-phase BLM can engage with the Cdt1-binding domain of Mcm6 using
MBD-C, defined by the WLVICI residues. The interaction between the MBD-C of BLM and the
C-terminal Cdt1-binding domain of Mcm6 is the most critical for the S-phase-specific interaction
between BLM and Mcm6 at active replisomes (Fig. 3D, Fig. 4E). In addition to MBD-C, the
interaction between the MBD-N of BLM and the N-terminus of Mcm6 also appears to remain
intact in S-phase and, together with the FYF residues (BLM residues 291-300), continues to
significantly contribute to the stability of the BLM/Mcm6 complex in unperturbed as indicated
by the complete loss of Mcm6 binding by the double mutant blm-QVFF-FYF. The QVFFFYF
mutation, which disrupts BLM/Mcm6 interaction in both G1 and S-phase, renders cells as
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sensitive to PDS and nearly as sensitive to HU as cells not expressing any BLM, highlighting the
significance of the BLM/Mcm6 interaction for normal cell function.
When S-phase cells are exposed to DNA damage, the S-phase specific interaction
between MBC-C and the Cdt1-binding domain of Mcm6 remains essential for BLM/Mcm6
association. Interestingly, the FYF residues (BLM residues 291-300), which play no significant
role in G1 and in unperturbed S-phase, become essential for the DNA-damage-specific
BLM/Mcm6 interaction. These FYF residues are also critical for binding TopBP1 after DNA
damage (Fig. S4D). TopBP1 had previously been shown to bind BLM in unperturbed S-phase in
a manner that is dependent on phosphorylation of the nearby serine 304 (Blackford et al., 2015,
Wang et al., 2013). The FYF residues, in contrast, are required for a TopBP1/BLM interaction
after DNA-damage induction, and play no role in the TopBP1/BLM interaction in unperturbed Sphase (Fig. S4D).
Additionally, the VICI residues within MBD-C resemble an inverted SUMO-binding
motif 2 (SBM2, [V/I] [V/I]X[V/I] ), one of the three known SUMO-binding motifs (Minty et al.,
2000, Song et al., 2004, Hannich et al., 2005, Hecker et al., 2006). Non-covalent binding of
SUMO by residues V235/I236 in the VICI motif and nearby residues I218/L220 has been shown
to be important for sumoylation of BLM at lysines 317,331, 344 and 347 (Eladad et al., 2005,
Zhu et al., 2008). The possibility that MBD-C contains a SUMO-binding motif also raises the
possibility that the MBD-C mediated BLM/Mcm6 interaction might be regulated by the
SUMOylation status of Mcm6. In yeast, there is evidence of Mcm6 being SUMOylated in G1
and playing a regulatory role by counteracting MCM phosphorylation to impair replication
initiation (Wei and Zhao, 2016). However, it is currently unknown if human Mcm6 is
SUMOylated, and if so, whether SUMOylation plays a similar role in the G1/S transition. Our
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observation that MBD-C mediates BLM/Mcm6 interaction in S-phase, prima facie suggests that
this association is independent of SUMOylation status. Moreover, we show that as BLM
localizes to PML in late S-phase its the overlap with Mcm6 foci decreases (Fig. 1G, Fig S1H),
suggesting that BLM/Mcm6 and BLM/PML interactions occur at different time points within Sphase.
It is interesting to note that Cdt1 is degraded rapidly upon exposure of cells to ultraviolet
light and ionizing radiation (Higa et al., 2003, Tanaka et al., 2017). In contrast, we observed that
exposure of early-to-mid-S-phase cells to CPT induced a rapid increase in Cdt1 levels and
colocalization of Cdt1 with Mcm6/BLM foci. These Cdt1/Mcm6/BLM foci accumulated just as
Mcm6/BLM foci disappeared (Fig. 3B), suggesting that Cdt1 is recruited to replisomes rather
than to new origins. What could the role of Cdt1 association with replisomes after DNA damage
be? The low concentration of CPT (1 μM) used in this study induces single-strand nicks that lead
to DSBs upon encounter with a replication fork (Helleday, 2003, Holm et al., 1989). Such
damage-induced, one-ended DSBs in S-phase are processed and become substrates for
homologous recombination. In budding yeast, they can be repaired by break-induced replication
(BIR) that is initiated by Rad51-dependent strand invasion of a homologous duplex, such as the
undamaged sister chromatid (Llorente et al., 2008). Single-strand invasion leads to formation of
a displacement (D)-loop where the invading 3’end can initiate new DNA synthesis. Since a
second DSB end is not available, this replicating D-loop can migrate until it encounters another
replication fork or the end of the chromosome. Although this type of DNA replication appears to
be different from that initiated at origins, it requires all of the essential replication factors
(Lydeard et al., 2010). Interestingly, the list also includes Cdt1, but not other factors specific for
pre-RC formation, such as ORC or Cdc6. This suggests that Cdt1 performs important replication
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functions outside of pre-RC assembly in G1, possibly the establishment of recombinationdependent replication forks in S-phase (Lydeard et al., 2010).
How Cdt1 could perform this function at collapsed replication forks remains to be
discovered, but there may be some clues. For example, Cdt1 has been shown to stabilize MCM
in a conformation where the ring is open at the Mcm2/5 interface and this conformation inhibits
MCM’s ATPase activity, which is essential for CMG function (Frigola et al., 2017). Thus, one
could envisage a scenario where, by favoring the open ring conformation, recruitment of Cdt1 to
stalled replisomes (Cdt1/MCM/BLM foci) may contribute to the intra-S-phase DNA-damage
response by halting replisomes and by allowing transfer of opened MCM rings to establish new
forks at D-loops. Moreover, Cdt1 could regulate chromatin compaction surrounding stalled
replisomes through its association with histone de/acetyltransferases (Miotto and Struhl, 2008,
Wong et al., 2010). A later role in the re-establishment of active replisomes at DNA-damage
sites is also plausible as Cdt1 has been shown to help recruit Cdc45 for formation of the active
CMG helicase (Ballabeni et al., 2009).
Finally, we found that Mcm6 association with BLM in G1 phase diminished Mcm6
association with Cdt1 (Fig. 4B). In fact, twice as many Mcm6 foci colocalized with Cdt1 in the
absence of BLM as in the presence of BLM, and disrupting the BLM/Mcm6 binding by
introducing the QVFF mutation was nearly as effective in promoting the Mcm6/Cdt1 association
as eliminating BLM. This ability of BLM to compete with Cdt1 for Mcm6 binding in vivo is also
supported by reciprocal co-immunopreciptations of BLM, Mcm6 and Cdt1 from G1 cells and of
equimolar amounts of the recombinant proteins in vitro. While the functional significance and
the strength of the competition between BLM and Cdt1 is currently unclear, increasing BLM
levels could play a role in displacing rapidly diminishing amounts of Cdt1 from Mcm6 or
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preventing Cdt1 re-association with Mcm6 after MCM loading until Cdt1 is eliminated in Sphase.
METHODS
Experimental Model and Subject Details
GM00637 (BLM+/+) and GM00637-derived KSVS1452 (BLM-/-) fibroblast cells were
maintained in Modified Eagle’s Medium (MEM) supplemented with 10% fetal bovine serum
(FBS), 1% penicillin-streptomycin-glutamine (PSG) and 2 mM L-glutamine.
CRISPR/Cas9-mediated BLM knockout
A diploid BLM knockout cell line was derived from the GM00637 cell line using a
CRISPR/Cas9 mediated genome engineering protocol (Ran et al., 2013). Briefly, guide RNA
(gRNA) sequences targeting exon 8 within BLM were designed using the CRISPR guide design
tool, which identifies and ranks suitable target sites and predicts off-target sites for each intended
target (http://tools.genome-engineering.org). gRNA sequences with the highest score and least
off-target impacts were cloned into the pSpCas9(BB)-2A-Puro vector and transfected into
GM00637 using Lipofectamine 2000 (Invitrogen). Selection and clonal isolation was performed
in the presence of 0.125 µg/mL puromycin. BLM knockout clones were verified by sequencing
and immunoblotting. Frameshift mutations within clone KSVS1452 resulted in the following
protein consequence:
GM00637:
BLM exon 8:
GACAAGTCAGCACAAAATTTAGCATCCAGAAATCTGAAACATGAGCGTTTCCAAAG
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TCTTAGTTTTCCTCATACAAAGGAAATGATGAAGATTTTTCATAAAAAATTTGGCCT
GCATAATTTTAGAACTAATCAGCTAGAGGCGATCAATGCTGACTGCTTGGTGAAGAC
TGTTTTATCCTGATGCCGACT
BLM:
DKSAQNLASRNLKHERFQSLSFPHTKEMMKIFHKKFGLHNFRTNQLEAINAALLGEDCF
ILMPT
KSVS1452:
BLM exon 8 (c.del2040_2046; g.del90,763,123_90,763,130):
GACAAGTCAGCACAAAATTTAGCATCCAGAAATCTGAAACATGAGCGTTTCCAAAG
TCTTAGTTTTCCTCATACAAAGGAAATGATGAAGATTTTTCATAAAAAATTTGGCCT
GCATAATTTTAGAACTAATCAGCTAGAGGCGATCAATGCTGACTGAAGACTGTTTTA
TCCTGATGCCGACT
BLM (p.Leu681LysTer686):
DKSAQNLASRNLKHERFQSLSFPHTKEMMKIFHKKFGLHNFRTNQLEAINAALKTVLS.
BLM exon 8 (c.delins2036_2041AG; g.delins90,763,119_90,763,124AG):
GACAAGTCAGCACAAAATTTAGCATCCAGAAATCTGAAACATGAGCGTTTCCAAAG
TCTTAGTTTTCCTCATACAAAGGAAATGATGAAGATTTTTCATAAAAAATTTGGCCT
GCATAATTTTAGAACTAATCAGCTAGAGGCGATCAATGCTGAGTTGGTGAAGACTGT
TTTATCCTGATGCCGACT
BLM (p.Leu678AlaTer686):
DKSAQNLASRNLKHERFQSLSFPHTKEMMKIFHKKFGLHNFRTNQLEAINAELVKTVLS.
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Cell cycle synchronization and replication stress induction
For synchronization in G1 phase, cells were blocked in G2/M by serum starvation
followed by nocodazole treatment (Xu et al., 2009). After being cultured in serum-free media for
22 hr, cells were released into media containing 10% FBS for 2 hr. Subsequently, they were
treated with 50 ng/mL nocodazole for 16 hr before synchronized progression into G1 phase.
For synchronization in S-phase, cells were arrested at G1/S using a double-thymidine block
(Jackman and O'Connor, 2001). Exponentially growing cells were cultured with 2 mM
thymidine (Acros Organics) for 12 hr, released into fresh media for 16 hr and back into media
supplemented with 2 mM thymidine for 14 hr. Three hours into S-phase, cells were treated with
1 μM camptothecin (CPT) for 1 hr and released into CPT-free media. Cells from time points
before, during and post CPT-treatment were used for immunoprecipitations and co-localization
analysis.
Immunoprecipitations
Nuclear lysates were prepared from exponentially growing cells for
immunoprecipitations. Briefly, cells were lysed (20 mM Tris pH 7.4, 10 mM KCl, 1 μM EDTA,
0.2% NP40, 50% glycerol, 0.6 mM βME, 1 mM PMSF and protease inhibitor cocktail [Pierce])
for 2 min on ice to isolate nuclei. The nuclei were lysed with nuclear lysis buffer (20 mM Tris
pH 7.4, 10 mM KCl, 0.4 M NaCl, 1 μM EDTA, 50% glycerol, 0.6 mM βME, 1 mM PMSF, and
protease inhibitor cocktail) supplemented with 25 U/mL benzonase (Novagen) (Rios-Doria et al.,
2009). Protein concentrations were determined using the Bradford assay and 1 mg nuclear
lysates were precleared with 30 µl Protein G Agarose (Pierce) at 4°C for 1 hr. The precleared
lysates were incubated overnight at 4°C with end-over-end mixing with either anti-BLM A300135

110A (4 μg; Bethyl), anti-MCM6 H8 (4 μg; Santa Cruz), anti-Cdt1 EPR17891 (2 μg; Abcam) or
non-specific IgG crosslinked to Protein G Agarose (Pierce). The complexes were washed
extensively with nuclear lysis buffer before elution. For LC-MS/MS, complexes were eluted in
50 μl 0.2 M glycine, pH 2.6 and immediately neutralized with 50 μl Tris, pH 8.0. For SDSPAGE, complexes were eluted in 50 μl 2X Laemmli sample buffer by boiling at 95°C for 10
min.
Mass spectrometric analysis
Immunoprecipitation eluates were prepared for mass spectrometric analysis using the
FASP Protein Digestion Kit (Expedeon) (Manza et al., 2005). Proteins were digested overnight
by the addition of sequencing grade modified trypsin (Promega) in a 1:50 ratio to protein.
Samples were desalted using C18 columns, concentrated in a vacuum concentrator and
resuspended in 0.1% formic acid in H2O. Mass spectrometric analysis was performed on a Q
Exactive Plus (Thermo). LC-MS/MS data was analyzed by using MaxQuant processing suite
(Cox and Mann, 2008). The identified spectra were compared against the UniProt reference
proteome data set for Homo sapiens (Proteome ID: UP000005640). The identified data set was
sorted to only include entries with no identified peptides in eluates from non-specific IgG
immunoprecipitations.
Immunofluorescent assays
Cells were cultured on glass coverslips (Corning) in a 6 well plate for at least 24 hr
before cell cycle synchronization. For analyses in the presence of plasmid borne protein
expression, cell cycle synchronization was initiated 24 hr post-transfection with Lipofectamine
2000. Cells at indicated time points within G1 and S-phase were washed with PBS and fixed
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using 4% paraformaldehyde (PFA; Life Technologies) for 15 min at room temperature (RT). The
cells were permeabilized by incubating with 0.25% Triton-X-100 in PBS for 15 min at RT. After
blocking in 1% BSA in PBS-T (PBS+0.1% Tween-20) for 30 min, the cells were incubated
overnight at 4°C with the following primary antibody dilutions prepared in the blocking buffer:
anti-BLM (C-18) (1:50; Santa Cruz), anti-MCM6 (H-8) (1:50; Santa Cruz), anti-Cdt1 EPR17891
(1:100; Abcam), anti-BLM (1:200; Abcam), anti-MCM6 (1:500; Sigma-Aldrich), anti-53BP1 (E10) (1:50; Santa Cruz) or anti-PML (PG-M3) (1:50; Santa Cruz). Cells were washed with PBS-T
and incubated for 1 hr at RT with the following secondary antibody dilutions prepared in the
blocking buffer: goat anti-Rabbit IgG (H+L) Cross-Adsorbed Secondary Antibody, Alexa Fluor
405 (2 ug/mL; ThermoFisher Scientific), goat anti-Mouse IgG (H+L) Cross-Adsorbed Secondary
Antibody, Alexa Fluor Plus 488 (2 ug/mL; ThermoFisher Scientific), donkey anti-Rabbit IgG
(H+L) Cross-Adsorbed Secondary Antibody, Alexa Fluor 555 (4 ug/mL; ThermoFisher
Scientific) or donkey anti-Goat IgG (H+L) Secondary Antibody, Alexa Fluor 647 (6 ug/mL;
Abcam). Cells were washed with PBS-T and the coverslips were mounted using VectaShield
(Vector Labs) onto glass slides (Fisher). For EdU co-staining analyses, cells were first labeled
with EdU for 15 mins using the Click-iT Plus EdU Alexa Fluor 594 Imaging Kit (ThermoFisher
Scientific) as per the protocol provided. This was followed by primary and secondary antibody
incubations as described previously. Images were acquired using an imaging system consisting
of a PerkinElmer UltraVIEW imager and a Zeiss AxioVert 200 inverted microscope equipped
with a 63x/1.4 Oil DIC Plan-Apochromat 0.19/0.17 objective. Foci from 30 merged images were
counted for co-localization. Significance was assigned using a two-tailed Mann Whitney test and
p-values < 0.05 were considered significant.
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Mammalian hybrid assay
Using the Matchmaker Mammalian Assay Kit 2 (Clontech), BLM and MCM6 were
cloned into the pVP16-AD and pM-DBD vectors respectively. Subsequently, pVP16-BLM and
pM-MCM6 were used to generate fragments as well as mutants using primers described in Table
S1. Interactions were assayed by co-transfecting them with the pG5SEAP reporter vector using
Lipofectamine 2000. 72 hr post-transfection, activity of secreted human placental alkaline
phosphatase (SEAP) expressed by the reporter vector was determined using the Great EscAPe
SEAP Fluorescence Detection Kit (Clontech). According to the protocol provided, media from
wells with the co-transfected cells was incubated with a fluorescent SEAP substrate in 96-well
flat bottom non-binding microplates (Greiner). Fluorescence was detected at 440 nm after
excitation at 340 nm in a Gen5 Microplate Reader (BioTek). All co-transfections were set up in
triplicate and SEAP activity was expressed in terms of relative fluorescence units (RFU).
Competitive binding assay
Purified human BLM and purified human MCM6 (Abcam) were immunoprecipitated
from two sets of mixtures also containing purified human Cdt1 (Origene) in IP buffer (25mM
Tris, 150mM NaCl; pH 7.2) (Yanagi et al., 2002). In the first set, 0.5 pM each of BLM and
MCM6 were mixed in the presence of increasing concentrations (0, 0.5, 0.75, 1, 1.25 and 1.5
pM) of Cdt1 and Protein-G agarose beads crosslinked with anti-BLM (Bethyl) or non-specific
IgG. In the second set, 0.5 pM each of Cdt1 and MCM6 were mixed in the presence of
increasing concentrations (0.5, 0.75, 1, 1.25 and 1.5 pM) of BLM and Protein-G agarose beads
crosslinked with anti-MCM6 (Santa Cruz) or non-specific IgG. Both sets were incubated for 2 hr
at 4°C with end over end mixing. The complexes were washed with IP buffer and
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immunoprecipitates were dissolved in 20 μl 2X Laemmli sample buffer by boiling at 95°C for 10
min.
Nuclease-insoluble chromatin fraction isolation
Nuclease-insoluble chromatin fraction was isolated from cells before, during and after
being released from 1 μM CPT-treatment in S-phase (Moiseeva et al., 2017, Aygun et al., 2008).
Cells were lysed with cytoplasmic lysis buffer (10 mM Tris pH 7.9, 0.34 M sucrose, 3 mM
calcium chloride, 2 mM magnesium acetate, 0.1 mM EDTA, 0.5% NP40, and protease inhibitor
cocktail) for 2 min on ice to isolate nuclei. The nuclei were lysed with nuclear lysis buffer
(20 mM HEPES pH 7.9, 3 mM EDTA, 10% glycerol, 150 mM potassium acetate, 1.5 mM
magnesium chloride, and 0.1% NP40 and protease inhibitor cocktail) for 30 min on ice. The
pelleted chromatin was incubated with nuclease incubation buffer (150 mM HEPES pH 7.9,
1.5 mM magnesium chloride, 10% glycerol, 150 mM potassium acetate, and protease inhibitor
cocktail) supplemented with 0.15 U/μL benzonase (Novagen) for 10 min in a 37°C shaker. The
nuclease-insoluble chromatin fraction was dissolved in 20 μl 2X Laemmli sample buffer by
boiling at 95°C for 10 min.
Cell survival assay
Cells were seeded at a density of 1000 cells/well in a 6-well plate 24 hr post-transfection.
They were released into media supplemented with pyridostatin (PDS; 0, 2, 4, 6, 8 and 10 μM) 24
hr after seeding and allowed to grow for 3 days. Alternately, 24 hr post-transfection, 1000
cells/well were seeded in a 6-well plate. They were released into media supplemented with
hydroxyurea (HU; 0, 0.1, 0.2, 0.3, 0.4 and 0.5 mM) 24 hr after seeding. After 48 hr, the cells
were released into drug-free media and allowed to grow for 7 days. Cells were washed with PBS
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before being fixed in 3:1 (vol/vol) methanol‐acetic acid and stained with 0.01% crystal violet.
Colonies containing more than 50 cells were scored as survivors.
FIGURES

Figure 4.1. BLM is in a complex with Mcm6 in G1 and S-phase
(A) Co-immunoprecipitations of endogenous BLM were performed in triplicate on nuclear
extracts from GM00637 cells in mid-S-phase and peptides identified by mass spectrometry. The
same analysis in triplicate for the isogenic BLM knockout cell line (KSVS1452) yielded zero hits
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for the listed proteins. Cell lines GM00637 and KSVS1452 are an isogenic pair of a BLM+/+ and
a CRISPR-mediated BLMKO cell line, respectively. See Fig. S1A-G and Methods for details on
construction and characterization of the KSVS1452 cell line. (B) Reciprocal coimmunoprecipitations of recombinant human BLM and Mcm6. (C) Reciprocal
coimmunoprecipitations of endogenous BLM and Mcm6 from nuclear extracts of GM00637
cells were performed in G1 and S-phase. (D) BLM foci formation in G1 and S-phase and
colocalization with Mcm6 (E) BLM colocalization with Mcm6 at active replisomes in S-phase as
indicated by EdU incorporation. As expected, BLM foci are not detected in the KSVS1452 cell
line. (F) Colocalization of all BLM foci with Mcm6 in G1. Blm, Mcm6 and Mcm6/BLM foci
were counted in nuclei from 30 cells. Mean+/-SD is shown. (G) Colocalization of BLM and
Mcm6 foci during the first half of S-phase. Appearance of occasional BLM foci that do not
colocalize with Mcm6 in the second half of S-phase. See Figure S1I-J for colocalization of these
BLM foci with PML and 53BP1. (H) Vast majority of BLM/Mcm6 foci in Sphase (>95%) are at
active replisomes, indicated by incorporation of EdU. As expected, EdU incorporation is not
observed in cells in G1. Foci in nuclei of 30 cells were counted. Data are presented as Mean+/SD.
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Figure 4.2. Two distinct sites in the disordered N-terminal tail of BLM interact with Mcm6
A) In a mammalian two-hybrid assay, residues 80-120 of BLM bind to the N-terminal domain of
Mcm6. See also Fig. S2B. (B) Residues 220-285 of BLM bind to the C-terminal extension of
Mcm6, which contains a winged-helix domain that also binds Cdt1 during pre-RC formation.
See also Fig. S2C. (C) MBD-N contains a conserved PIP-box-like motif. (D) MBD-C contains
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four conserved hydrophobic residues embedded in an acidic patch. Two additional hydrophobic
residues nearby are conserved in mammals. (E) Mutation of QVFF residues in MBD-N to
alanine disrupts BLM interaction with the N-terminus of Mcm6 in a two-hybrid assay. Despite
the PIP-box-like motif, this segment of BLM is not involved in a novel interaction between BLM
and PCNA (See Fig. S2D). (F) Mutation of VICI and WLVICI residues in MBD-C to alanine
disrupt the BLM interaction with the C-terminus of Mcm6 in a two-hybrid assay. MBD-N,
Mcm6 N-terminus binding domain; MBD-C, Mcm6 C-terminus binding domain. (G) Locations
of the Mcm6 binding sites MBD-N and MBD-C in BLM and their interaction sites in Mcm6.
Differences between means were analyzed by a t-test and presented as ** (p<0.01) and
****(p<0.0001).
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Figure 4.3. MBD-N and MBD-C regulate differential association of BLM with Mcm6 in G1
and S-phase
(A) GM00637 and KSVS1452 cells were synchronized in G1, released into S-phase for 3 hours,
exposed to 1μM CPT for 1 hour and released into fresh media for 45 minutes. Reciprocal
coimmunoprecipitation of BLM, Cdt1 and Mcm6 were performed in G1, S-phase and during
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recovery from CPT exposure. (B) Exposure of BLM+/+ cells to CPT in mid-S-phase causes a
rapid increase in Cdt1 expression levels, which is accompanied by the appearance of
BLM/Mcm6/Cdt1 and Mcm6/Cdt1 foci, respectively. Removal of CPT leads to rapid
degradation of Cdt1 levels and a decrease of BLM/Mcm6/Cdt1 foci. See also Fig. S6A and S6B
Cdt1 degradation in unperturbed S-phase and for the effect of CPT on BLMKO cells. (C)
KSVS1452 cells expressing the blm-QVFF mutant were analyzed as in (A). See also Fig. S4A
for co-immunoprecipitation of Mcm6 with BLM carrying the milder QVF mutation and Fig. S4B
for co-immunoprecipitation Mcm6 with BLM carrying a deletion of residues 1- 160, which
encompass MBD-N. (D) KSVS1452 cells expressing the blm-WLVICI mutant were analyzed as
in (A). See also Fig. S4C for co-immunoprecipitation of Mcm6 with BLM carrying the milder
VICI mutation (E) Sequence alignment of residues 284-308 of human BLM with BLM
homologs from other vertebrates. Residues mutated in the blm-FYF mutant are labeled with an
asterisk. Phosphorylation of serine 304 was previously reported to play a role in BLM/TopBP1
binding in unperturbed S-phase (Blackford et al., 2015) (F) KSVS1452 cells expressing the blmFYF mutant were analyzed as in (A). See also Fig. S4D for the requirement of the FYF residues,
but not MBD-C, for BLM/TopBP1 binding and Fig. S4E for the importance of the FYF residues
for BLM/TopBP1 binding after CPT treatment, but not in unperturbed S-phase or G1 (G) Effect
of the blm-FYF and blm-QVFF-FYF mutations on the BLM/Mcm6 interaction in a two-hybrid
assay. Mean } SD is shown. Differences between means were analyzed by a t-test and
presented as *** (p<0.001). (H) QVFF residues in MBD-N and FYF residues cooperate to bind
Mcm6 in S-phase. KSVS1452 cells expressing the blm-QVFF-FYF mutant were analyzed in G1
and S-phase as in (A). (I) BLM is required for timely resumption of DNA replication after
exposure to CPT. Based on colocalization with EdU foci, the vast majority of BLM/Mcm6 foci
in BLM+/+ cells (94%) and in BLMKO (KSVS1452) cells (95%) are replicating during
unperturbed S-phase (p=0.41). After a 45-minute release from 1-hour CPT exposure,
significantly fewer Mcm6 foci are replicating in BLMKO cells (26%) than in BLM+/+ cells (64%).
See also Fig. S6D. Differences between foci numbers were analyzed by a Mann-Whitney test
and are shown as ****(p<0.0001); n.s., not significant. (J) Clonogenic assays were performed to
measure survival of KSVS1452 cells expressing BLM mutants to increasing concentrations of
the G4-stabilizer pyridostatin (PDS) and (K) hydroxyurea (HU). Mean +/-SD is reported.
Significance of differences between means was analyzed by a t-test and is indicated by *
(p<0.05), ** (p<0.01), *** (p<0.001) and ****(p<0.0001).
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Figure 4.4. Effects of MBD-N, MBD-C, and FYF mutations on association between BLM,
Mcm6 and Cdt1 in vivo
(A) BLM, Mcm6 and Cdt1 foci were counted in 30 nuclei from KSVS1452 (BLMKO) cells in
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G1 phase transfected with plasmids expressing BLM mutants that disrupt the interaction with
Mcm6. (B) Quantification of Mcm6 foci and Mcm6/Cdt1 foci in KSVS1452 (BLMKO) cells
transfected with BLM mutants. Numbers above the columns indicate the percentage of Mcm6
foci that colocalize with Cdt1 (C) The blm-QVFF mutation, which disrupts BLM/Mcm6 binding
in G1, or absence of BLM (vector) increases Cdt1/Mcm6 interaction in G1. Reciprocal coimmunoprecipitations of Cdt1 and Mcm6 were performed on KSVS1452 (BLMKO) cells in G1
phase transfected with empty vector or with plasmids expressing BLM or the blm-QVFF mutant.
(D) BLM and Cdt1 compete for binding to Mcm6 in vitro. Coimmunoprecipitation of equimolar
amounts of recombinant Mcm6 (0.5 μM) and recombinant BLM (0.5 μM) is disrupted by
addition of increasing amounts of Cdt1 (0.5 – 1.5 μM). Co-immunoprecipitation of equimolar
amounts of recombinant Mcm6 (0.5 μM) and recombinant Cdt1 (0.5 μM) is disrupted by
increasing amounts of BLM (0.5 – 1.5 μM). See also Fig. S5 for reciprocal coimmunoprecipitations of the recombinant proteins. (E) BLM, Mcm6 and Cdt1 foci were counted
in 30 nuclei from KSVS1452 (BLMKO) cells in unperturbed S-phase transfected with plasmids
expressing BLM mutants (F) BLM, Mcm6 and Cdt1 foci were counted in 30 nuclei from
KSVS1452 (BLMKO) cells in S-phase 45 minutes after release from a 1-hour exposure to 1 μM
CPT transfected with plasmids expressing BLM mutants.

Figure 4.5. Model for the function of the BLM/Mcm6 interaction
In G1, BLM binds the N-terminal domain of Mcm6 via MBD-N, leaving the C-terminal
extension of Mcm6 free to bind Cdt1 for origin loading. Cdt1 binding overcomes the
autoinhibitory function of the C-terminal extension of Mcm6 and leads to ATP hydrolysis, Cdt1
release, and recruitment of the second MCM hexamer to origins. Upon S-phase entry, Cdt1 is
rapidly degraded through multiple pathways. BLM/Mcm6 interaction is now stabilized by
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binding the N- and C terminal extensions of Mcm6 through MBD-N, MBD-C and the FYF
residues in its disordered tail. In contrast to G1, the association between MBD-C of BLM and the
Cdt1-bindingdomain of Mcm6 is the dominant interaction in S-phase (filled rectangle) and
cooperation between MBD-N and the FYF residues contributes to this interaction (patterned
rectangles). BLM associates with Mcm6 in S-phase to support duplex unwinding by CMG when
it encounters G4s. BLM would also be able to unfold G4 structures that may form in singlestranded DNA behind the fork (dotted line). In addition to G4 unfolding, BLM also associates
with replisomes during replication stress. During exposure of cells to CPT, Cdt1 levels increase
rapidly and Cdt1 associates with Mcm6/BLM at replisomes (Fig. 3B). In addition to the Cdt1binding domain of Mcm6, Cdt1 also binds to other sites of Mcm6 and to other MCM subunits,
most prominently Mcm2 and Mcm4 (Frigola et al., 2017). BLM/Mcm6 interaction in cells
exposed to CPT is mediated by MBD-C binding to the C-terminal extension of Mcm6 and by the
FYF residues (filled rectangles). In contrast, BLM association with the N-terminal domain of
Mcm6 via the MBD-N site plays the smallest role in the DNA-damage response. The first 230
residues of the Nterminal tail of BLM encompassing MBD-N may bind DNA repair factors
instead of Mcm6. During CPT exposure, Cdt1 may be recruited to replisomes to inhibit MCM
ATPase activity to halt replication, to destabilize the Mcm2/5 interface to allow transfer of
MCM, or regulate chromatin openness near collapsed forks (see text for details).

148

5

7

5

PML
S phase (hours)
6

7

20
15
10
5
0

BLM
MCM6
PML
BLM/MCM6
BLM/PML
MCM6/PML
BLMMCM6/PML
BLM
MCM6
PML
BLM/MCM6
BLM/PML
MCM6/PML
BLMMCM6/PML
BLM
MCM6
PML
BLM/MCM6
BLM/PML
MCM6/PML
BLMMCM6/PML

Foci/Nucleus

25

PML
S phase (hours)
6

Figure S4.1. Characterization of the BLMKO cell line KSVS1452 generated by
CRISPR/Cas9-mediated biallelic disruption of BLM exon 8 in GM00637
(A) Single cell clones were screened by Western blotting for absence of BLM expression.
GM08505 is a skin fibroblast cell line from a Bloom’s syndrome patient, showing absence of
BLM expression. Fragment encompassing exon 8 was amplified by PCR, cloned and sequenced
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to identify the disruptions in both alleles of BLM exon 8. For exact changes DNA and amino acid
sequence changes identified in clone 6 (KSVS1452) see Methods. (B) Increased levels of sisterchromatid exchanges (SCEs) in KSVS1452. (C) SCEs in 1500 chromosomes for each cell line
were counted. Mean } SD is shown. (D) Delayed elimination of H2AX phosphorylation in
KSVS1452 after 1-hour exposure to camptothecin (CPT). (E) Quantification of γ-H2AX levels
in KSVS1452 and GM00637 cells after CPT exposure. Mean+/-SD is shown from three
experiments. (F) KSVS1452 cells are hypersensitive to hydroxyurea. Mean+/-SD is shown from
three experiments. (G) Neutral comet assay shows delayed repair of DNA double-strand breaks
after CPT exposure in KSVS1452 cells. 150 comets from three experiments per time point and
cell line were analyzed. Mean+/-SD is shown. Experiments in panels (B) – (G) were performed
exactly as previously described (Shastri & Schmidt, 2016). (H) Colocalization of BLM foci with
PML and Mcm6 in the second half of S-phase. 30 nuclei from GM00637 were analyzed for each
of the indicated time points. Mean+/-SD is shown. (I) Lack of colocalization of 53BP1 with
BLM foci in the second half of S-phase. 30 nuclei from GM00637 were analyzed for each of the
indicated time points. Mean+/-SD is shown.
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Figure S4.2. Identification of Mcm6 binding sites in the N-terminal tail of BLM
(A) BLM consists of a 647-residue long, intrinsically disordered N-terminal tail and a 770residue Cterminal helicase domain. Disorder scores for every residue were calculated in IUPred
(Dosztanyi et al, 2005). A disorder score of >0.5 indicates a discorded residue. (B) Two-hybrid
analysis of the interaction between the N-terminal domain of Mcm6 (residues 1-325) and
fragments of BLM. Mean } SD from three transfections is shown. Bottom panel shows the
Mcm6 and BLM fragments in combination with empty bait and prey vectors. (C) Two-hybrid
analysis of the interaction between fragments of the Cterminal domain of Mcm6 (residues 325821) and fragments of BLM. Mean } SD from three transfections is shown. Bottom panel
shows the Mcm6 and BLM fragments in combination with empty bait and prey vectors. (D)
Mutation of residues L107 and L108 or F111 in MBD-N to alanine does not affect Mcm6
binding in the two-hybrid assay. Mean } SD from three transfections is shown. (E) The first
160 residues of BLM, which include the PIP-box-like sequence in MBD-N that binds Mcm6, is
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not required PCNA binding. A BLM fragment encompassing the first 120 residues of BLM does
not bind PCNA. KSVS1452 cells were transfected with plasmids (p-AD) expressing BLM
mutants or fragments, and Mcm6 interaction was evaluated by co-immunoprecipitation.

Figure S4.3. Effect of DNA-damage induction and recovery on Cdt1 levels and replisome
activity
(A) Cdt1 levels were assessed by Western blotting in untreated BLM+/+ (GM00637) and
BLMKO (KSVS1452) cells and during a 1-hour exposure to 1 μM CPT followed by a 3- hour
release into fresh media. Cdt1 levels from three independent experiments were quantified against
GAPDH levels using ImageJ. Mean } SD is shown. (B) Foci formation between BLM, Mcm6
and Cdt1 was analyzed in 30 nuclei from GM00637 cells in unperturbed S-phase starting at 3
hours after release from G1. Average Cdt1 expression level from Figure S3A is overlayed on the
right Y-axis. For simplicity, only BLM, BLM/Mcm6, and BLM/Mcm6/Cdt1 foci are shown. (C)
Foci formation between BLM, Mcm6 and Cdt1 was analyzed in 30 nuclei from GM00637 cells
during 1-hour exposure to CPT and after release into fresh media. (D) Comparison of
colocalization of BLM, Mcm6 and BLM/Mcm6 foci with EdU foci in GM00637 and KSVS1452
cells in unperturbed S-phase and 45 minutes after release from CPT. Foci in 30 nuclei were
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analyzed for each condition. Mean } SD is shown. Significance of differences between foci
numbers was determined by a Mann-Whitney test.

Figure S4.4. Interactions between the N-terminal tail of BLM and Mcm6 and TopBP1
(A) BLM-QVF poorly interacts with Mcm6 in G1, but normally in S-phase. (B) An N-terminal
truncation of the first 160 residues of BLM fails to interact with Mcm6 in G1, but not in S-phase
or after CPT exposure. (C) BLM-VICI co-immunoprecipitates with Mcm6 in G1, but does so
poorly in S-phase, in the presence or absence of CPT. (D) The first 240 residues of BLM are
sufficient for Mcm6 binding, but not for TopBP1 binding. Cells were transfected with a plasmid
expressing BLM residues 1-240 and co-immunoprecipitation with Mcm6 and TopBP1 was
evaluated by Western blot. (E) TopBP1 coimmunoprecipitates with BLM in perturbed and
unperturbed S-phase. The blm-FYF mutation specifically disrupts the interaction between BLM
and TopBP1 after exposure to CPT. Cells were transfected with plasmid expressing BLM or
blm-FYF or with empty vector and co-immunoprecipitation with TopBP1 was evaluated by
Western blot.
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Figure S4.5. Interaction of recombinant Mcm6 with BLM and Cdt1
Reciprocal co-immunoprecipitations were performed using equimolar amounts of purified
human BLM and Mcm6 or purified human Cdt1 and Mcm6.

Figure S4.6. Colocalization of BLM with Mcm6 and 53BP1 in the absence and presence of
DNA damage
(A) BLM foci colocalize with 53BP1 after exposure to CPT. Foci were counted in 30 nuclei of
wildtype cells (GM00637) 45 minutes after removal of CPT. Cells not exposed to CPT did not
form 53BP1 foci. (B) Quantification of Mcm6 foci and Mcm6/BLM foci in KSVS1452
(BLMKO) cells transfected with BLM mutants in G1 phase, in S-phase (C) and 45 minutes after
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CPT exposure (D). Numbers above the columns indicate the percentage of BLM foci that
colocalize with Mcm6.
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CHAPTER FIVE:
PERSPECTIVES
Mutations and heterozygosity in BLM have been statistically associated with increased
susceptibility to cancers [1-11]. Likewise, single nucleotide polymorphisms (SNPs) in the noncoding region of BLM have been linked with various malignancies [12, 13]. Epidemiological
studies have provided evidence for a relationship between SNPs in genome stability maintenance
genes and putative cancer risk [14]. It has been suggested that rare SNPs play a role in human
diseases [15-17]. Of the 74 known coding SNPs in BLM resulting in missense variants, all but
three are rare with allele frequencies <0.05. However, the significance and disease association of
these missense variants were unknown. A study using humanized yeast model functionally
characterized selected non-synonymous coding SNPs in BLM for the first time and identified
BLM variants causing increased DNA-damage sensitivity [18]. Subsequently our study
described in Chapter Two functionally characterized these BLM variants in human cells [19].
Within the broader context of determining their biological relevance, disease association and
subsequent translation to clinical use, this can be perceived as the vital first step.
The next step would be to expand the functional annotation to all known BLM missense
variants, including variants predicted to be benign, intermediate as well as damaging in silico,
and provide functional evidence for their classification based on pathogenicity [20, 21]. The
functional status of these variants can be ascertained in GM08505 or KSVS1452 cells by using
the same functional complementation assays used in Chapters Two and Three. However, variants
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mapping to known protein interaction sites in the disordered BLM N-terminal region might not
be sensitive to the functional assays designed to test the impact of variants mapping to the
conserved C-terminal domains involved in helicase activity. Variants which disrupt BLM
interaction with some proteins but not others have not been identified yet and could play a role in
delineating BLM function in various pathways. Those mapping to regions predicted to contain
increased α-helical content and hypothesized to be involved in protein interactions in BLM can
be analyzed for loss of protein interaction and subsequent impact on protein function [22-24].
This could lead to the identification of a new class of separation of function BLM variants with
variable impact. The selection of functional assays to test the impact of such variants would be
dependent on the specific interaction interrupted. Overall, these functional assays would provide
evidence that certain phenotypes are the result of specific variants. This can be strengthened
further by reproducing these results in assays using primary patient cells or animal models. Such
comprehensive experimental evidence combined with allele frequencies in human population
could provide critical insights into disease association of these rare variants. Clinically, this
classification of variants can be useful in developing next-generation DNA screening (NGS)
panels for diagnosis as well as developing personalized therapy [21, 25-27].
Consistent with replication defects observed in Bloom syndrome cells and the ascribed
role of BLM in restarting replication forks, we have identified a novel interaction between BLM
and Mcm6, a component of the replicative MCM complex in Chapter Four. We hypothesize that
as a constitutive component of the replisome, BLM helps replication fork progression through
regions containing secondary DNA structures such as G-quadruplexes. Using pyridostatin to
stabilize G-quadruplex DNA, we have shown the necessity of BLM/Mcm6 interaction in
surmounting secondary structures in vivo. Further assays monitoring the response of the
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replisome/replication forks to secondary DNA structure formation would be required. Although
various specialized helicases have been shown to unwind G-quadruplex DNA, their selection and
recruitment to unwind such structures in vivo might depend on the specific structural
conformation and protein interactions [28]. Comparison studies have shown that unlike other
specialized helicases, BLM is unique in binding to G-quadruplex conformations non-selectively
[29, 30]. Coupled with our data identifying Mcm6 as a BLM interactor and the putative presence
of BLM at active replisomes, this is a strong implication of BLM being the main specialized
helicase assisting the replicative helicase in overcoming G-quadruplex formation during
replication. A reporter based assay in the presence and absence of BLM/Mcm6 interaction could
be used to monitor instability at loci predisposed to form G-quadruplex structures [31, 32].
Sequences with the potential to form G-quadruplexes are highly prevalent, including over
90% of DNA replication origins, and could form a frequent barrier to replication initiation [28,
33]. G-quadruplexes have been visualized in cells not undergoing replication, suggesting that
these could be pre-formed structures encountered by the replisome before replication [34]. Taken
together, our identification of BLM/Mcm6 interaction in G1 implies a novel role for BLM.
However, this requires further in vivo verification. One approach would be to use DNA combing
to investigate DNA replication origin firing in the presence and absence of BLM/Mcm6
interaction in G1 [35, 36]. Immunofluorescence analysis to test localization patterns of BLM and
components of pre-RC as well as pre-ICs through G1 and G1/S would be another approach to
dissect the function of BLM/Mcm6 interaction in G1. Furthermore, an IMT fluorescent probe
can be used for real-time monitoring of G-quadruplex DNA in G1 cells with and without
BLM/Mcm6 interaction. Our findings in Chapter Five open up the possibility of exploring G-
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quadruplex stabilization as a therapeutic approach in Bloom syndrome patients, who otherwise
face chemotherapy-induced toxicity [37-40].
Through our research, we have paved the way for disease-association studies with the
first functional evaluation of BLM variants of uncertain significance in human cells. Eventually,
we hope for the establishment of carrier screening panels for diagnosis and treatment options.
We have established a system to evaluate the global proteome to investigate pathways
dysregulated in the absence of functional BLM. Our discovery of cell cycle specific interaction
between BLM and Mcm6 provides mechanistic insights into some of the phenotypes observed in
Bloom syndrome cells. Furthermore, we indicate a novel role for BLM in G1. The functional
relevance of this interaction could be potentially translated to therapeutic benefits. We believe
that our contribution has led to a better understanding of BLM function and Bloom syndrome.
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